预约演示
更新于：2026-07-20
Elraglusib
更新于：2026-07-20
概要
基本信息
非在研机构 |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、罕见儿科疾病 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C22H13FN2O5 |
InChIKeyFARXPFGGGGLENU-UHFFFAOYSA-N |
CAS号1034895-42-5 |
关联
10
项与 Elraglusib 相关的临床试验NCT04832438
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma [ACC]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.
开始日期2030-12-18 |
申办/合作机构 |
NCT06896188
A Phase Ib Study of 9-ING-41 (Elraglusib), a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Modified FOLFIRINOX as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
This is a study of the combination of 9 ING-41 (elraglusib) and retifanlimab plus mFOLFIRINOX in patients with pancreatic cancer without prior systemic therapy for advanced disease. The safety lead-in cohort will consist of 6 patients, followed by dose de-escalation if necessary, based on safety assessments. After evaluating the safety and tolerability at the initial dose level, the study will proceed to an expansion cohort at the determined safe dose level, with the total maximum enrollment not exceeding 12 patients for the entire study.
开始日期2025-09-22 |
申办/合作机构 |
NCT05077800
A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease.
The names of the study drugs involved in this study are:
* 9-ING-41
* Losartan
* Ferumoxytol
* FOLFIRINOX (made up of 4 different drugs):
* 5-Fluorouracil (5-FU)
* Oxaliplatin
* Irinotecan
* Leucovorin
The names of the study drugs involved in this study are:
* 9-ING-41
* Losartan
* Ferumoxytol
* FOLFIRINOX (made up of 4 different drugs):
* 5-Fluorouracil (5-FU)
* Oxaliplatin
* Irinotecan
* Leucovorin
开始日期2022-03-21 |
申办/合作机构 |
100 项与 Elraglusib 相关的临床结果
登录后查看更多信息
100 项与 Elraglusib 相关的转化医学
登录后查看更多信息
100 项与 Elraglusib 相关的专利（医药）
登录后查看更多信息
44
项与 Elraglusib 相关的文献（医药）2026-05-01·NATURE MEDICINE
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Article
作者: Sahai, Vaibhav ; Weiskittel, Taylor ; Ploquin, Anne ; Giles, Francis J ; Ji, Yan ; Mazar, Andrew P ; Jaros, Mark ; Kavan, Petr ; Cervantes, Andres ; Ugolkov, Andrey ; Hiret, Sandrine ; Pernot, Simon ; Carneiro, Benedito A ; Lopez, Charles D ; Percent, Ivor J ; Coveler, Andrew L ; Fine, Gil ; Shroff, Rachna T ; Carr, Ryan ; Seifarth, Chris ; Bekaii-Saab, Tanios S ; Mulcahy, Mary ; Mahalingam, Devalingam ; LoConte, Noelle K
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is one of the leading causes of cancer-related mortality, but advances in therapeutic treatments remain limited. Elraglusib (9-ING-41), an inhibitor of GSK-3β, exhibits a multimodal mechanism of action based on antitumor activity in preclinical models of cancer, including pancreatic. The efficacy and safety of elraglusib with gemcitabine plus nab-paclitaxel (GnP) were assessed in patients with previously untreated mPDAC. In an open-label, international, multicenter, phase 2 study, patients were randomized 2:1 to weekly elraglusib/GnP or GnP alone. Primary endpoints were median overall survival (OS) and 1-year survival rate. The prespecified modified intention-to-treat population included 155 patients on elraglusib/GnP and 78 on GnP. As of the data cutoff of 27 April 2025, elraglusib/GnP improved median OS by 2.9 months and decreased the risk of death by 38% versus GnP (median OS 10.1 months versus 7.2 months, respectively (hazard ratio 0.62; 95% confidence interval 0.46 to 0.84; P = 0.01)). The 1-year survival rates were 44.1% versus 22.3%, respectively. The safety profile of elraglusib/GnP was manageable. The most common grade 3 or higher treatment-emergent adverse events (TEAEs) with elraglusib/GnP versus GnP alone were neutropenia (52.3% versus 30.8%), anemia (25.2% versus 29.5%) and fatigue (16.8% versus 5.1%). Explorative correlative analyses demonstrated that baseline circulating immune-related factors (that is, CXCL2 and TRAIL ligands) were associated with improved survival in the elraglusib/GnP arm. Treatment was accompanied by increases in intratumoral cytotoxic immune cell populations. Together, these findings support the clinical activity of elraglusib/GnP as first-line treatment in mPDAC and provide a biological context for the observed survival benefit. Based on the results of this phase 2 trial, a phase 3 trial is being planned. ClinicalTrials.gov registration: NCT03678883.
2026-01-06·CLINICAL CANCER RESEARCH
Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma
Article
作者: Hanna, Glenn J. ; Jo, Vickie Y. ; Haddad, Robert I. ; Ugolkov, Andrey ; Scarfo, Nicole ; Wong, Kristine ; Sehgal, Kartik ; Mazar, Andrew ; Dennis, Michael J. ; O’Neill, Anne ; Shin, Kee-Young ; Bedard, Veronica
Abstract:
Purpose::
Glycogen synthase kinase 3β (GSK-3β) is a known therapeutic target in cancer. Aberrant nuclear GSK-3β (nGSK-3β) expression has been shown in some salivary gland cancers. Elraglusib is a small-molecule GSK-3β inhibitor with immunomodulatory potential. We hypothesized that elraglusib plus platinum-based chemotherapy and immunotherapy priming would be a novel treatment approach for salivary gland cancer.
Patients and Methods::
This phase II, open-label trial enrolled patients with recurrent or metastatic salivary gland cancer [adenoid cystic carcinoma (ACC) vs. other subtypes] with disease progression in the preceding year. Cohort 1 received elraglusib (15 mg/kg i.v. on days 1 and 4) plus carboplatin (AUC = 5) or cisplatin (75 mg/m2) every 21 days. Cohort 2 received two cycles of pembrolizumab (200 mg i.v.) every 21 days prior to the same regimen. The primary endpoint included best overall response rate (ORR) by RECIST v1.1 (>5/32 in response to detect 25% ORR).
Results::
Thirty-two patients were enrolled, including 15 (47%) with ACC and 17 (53%) with non-ACC. The best ORR was 9.4% [3/32; 95% confidence interval (CI), 2–25; three partial responses, all non-ACC]. Nineteen (59%) patients achieved stable disease. The median duration of response was 6.9 months. Common treatment-related adverse events were anemia (22, 69%), nausea (16, 50%), and neutropenia (14, 44%). At the median follow-up of 18.3 months, the median progression-free survival was 6.4 months (95% CI, 2.3–8.8), and the median overall survival was 18.6 months (95% CI, 9.7–29.4) overall. The median nGSK-3β expression was 50% versus 2% for responders versus nonresponders.
Conclusions::
The trial did not meet its primary endpoint, although 18% of patients with non-ACC treated with immune priming followed by cisplatin plus elraglusib achieved a response. Higher nGSK-3β expression was observed in tumor samples obtained from responders.
2025-12-31·CANCER BIOLOGY & THERAPY
Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL)
Article
作者: Guo, Xutao ; Zhang, Yunxia ; Wei, Xiaolei ; Shi, Pengcheng ; Zheng, Haiqing ; Lei, Haohao
BACKGROUND:
Double-hit lymphoma (DHL) exhibits aggressive behavior due to dysregulated proliferation and resistance to apoptosis. Current therapies, including R-CHOP, show limited efficacy, necessitating novel strategies. 9-ING-41, a novel ATP-competitive small-molecule inhibitor that targets glycogen synthase kinase-3β (GSK-3β), has emerged as a promising therapeutic agent because of its ability to disrupt oncogenic signaling pathways associated with tumor progression and treatment resistance. However, the antitumor effects of 9-ING-41 in DHL remain unclear.
MATERIALS AND METHODS:
DHL cell lines (Karpas-422 and SuDHL2) were treated with venetoclax and 9-ING-41, either alone or in combination. Cell viability in cytotoxicity assays was assessed using the CCK-8 assay, while apoptosis and cell cycle changes were analyzed via flow cytometry. Western blotting was employed to evaluate alterations in the levels of GSK-3β and WNT/β-catenin pathway proteins following treatment.
RESULTS:
In preclinical studies utilizing DHL cell models, the single agent 9-ING-41 demonstrated robust biological activity through inducing significant G1/S phase cell cycle arrest and triggering apoptosis. When coadministered with venetoclax, a clinically approved BCL-2 inhibitor, the combination exhibited marked synergistic cytotoxicity in DHL cells, achieving superior inhibitory effects compared to either agent alone. The combined treatment enhanced cell cycle arrest, significantly reducing the number of S-phase cells and reinforcing G0/G1 arrest. Further mechanistic studies revealed that the combination modulated key proteins in the GSK-3 pathway and downstream WNT/β-catenin pathway, revealing a potential synergistic mechanism.
CONCLUSION:
The demonstrated single-agent efficacy and combination synergy with venetoclax support the potential of 9-ING-41 as a novel therapeutic strategy for DHL. These findings provide a proof-of-concept that may serve as a basis for future preclinical investigations in DHL.
90
项与 Elraglusib 相关的新闻（医药）2026-07-15
从肿瘤内放射、TTFields到RAS抑制剂，胰腺癌创新治疗正在突破“癌王”胰腺癌化疗瓶颈。
2026年，胰腺癌研发连续迎来多个重要进展。
2月，Novocure的肿瘤治疗电场设备Optune Pax获FDA批准（电场治疗破冰“癌王”，实体瘤版图扩张丨首个局晚期胰腺癌三期成功）；
5月，RAS(ON)抑制剂daraxonrasib的Ⅲ期研究数据显示，中位总生存期达到13.2个月，对照化疗组为6.7个月（深度：一线ORR达82%！Revolution第二款RAS抑制剂如何助其迈向胰腺癌领军者？）；
7月，OncoSil Medical又在2026 ESMO胃肠道肿瘤大会公布TRIPP-FFX研究结果：磷-32微粒联合FOLFIRINOX治疗不可切除局部晚期胰腺癌，达到安全性/耐受性和16周局部疾病控制率两项共同主要终点。
这些进展并不来自同一技术方向，却释放出一个共同信号：胰腺癌正在从长期由细胞毒化疗主导，转向“局部物理治疗＋RAS靶向＋微环境调节＋精准分层”并行探索的新阶段。一、P-32微粒是什么？
TRIPP-FFX研究使用的OncoSil并不是传统意义上的抗癌药，而是一种植入式近距离放射治疗器械。
OncoSil由含放射性同位素磷-32的微粒及专用悬液组成。医生在内镜超声引导下，将微粒经穿刺针直接注入胰腺肿瘤，使其在肿瘤内部持续释放β射线。
P-32具有几个适合局部治疗的物理特征：
主要释放β射线，在组织中的作用距离通常不足1 cm；
物理半衰期约14.3天；
约98%的预定辐射剂量在81天内释放；
微粒长期停留于肿瘤内，但放射性会随P-32衰变逐渐消失；
植入活度根据肿瘤体积计算，TRIPP-FFX的目标吸收剂量约为100 Gy。
因此，OncoSil的核心并不是“全身递送放射性药物”，而是将微型放射源固定在肿瘤内部，尽量提高局部吸收剂量，同时降低胃、十二指肠和周围大血管等正常结构受到的照射。二、为什么胰腺癌需要局部强化？
胰腺导管腺癌具有致密间质、低灌注和免疫抑制性微环境。药物进入肿瘤内部的效率有限，而胰腺又邻近十二指肠、胃、胆管和腹腔重要血管，使传统放疗的剂量提升受到限制。
对于不可切除局部晚期患者，治疗需要同时解决两个问题：
全身化疗控制潜在微转移；
局部治疗尽可能缩小或稳定原发病灶，避免血管侵犯、疼痛、胆道梗阻及其他局部进展。
P-32微粒与FOLFIRINOX的组合逻辑正在于此：FOLFIRINOX负责全身控制，P-32负责在肿瘤内部持续释放辐射。其定位不是取代化疗，而是补强化疗对原发病灶的局部控制。三、TRIPP-FFX达到了主要终点，但没有证明优于化疗
TRIPP-FFX是一项开放标签、多中心、随机Ⅱ期研究，共纳入88例不可切除局部晚期胰腺腺癌患者：45例接受P-32微粒联合FOLFIRINOX；43例接受单纯FOLFIRINOX；联合组计划在第4周进行一次P-32微粒植入；患者最多接受12个周期FOLFIRINOX。研究达到了安全性/耐受性和16周局部疾病控制率两项共同主要终点。
这组数据需要分层解读。
需要注意，这里的“研究成功”是指联合方案达到了预先设定的疗效标准，而不是战胜了对照组（研究没有按照“两组谁更优”进行统计设计）。联合组16周局部疾病控制率为82.2%，FOLFIRINOX组为86.0%。因此，现有结果只能说明P-32联合方案具有局部控瘤活性，尚不能证明其优于单纯FOLFIRINOX。
其次，联合组在ORR、肿瘤缩小幅度、PFS和OS方面呈现一致的数值优势，尤其是ORR从37.2%提高至55.6%，中位OS由15.8个月延长至18.2个月。但该研究被定义为随机、非比较性研究，样本量并未按照正式组间优效性检验设计，因此这些差异只能被视为疗效信号。
最后，两组手术切除率基本相同。联合组已切除患者的R0切除率较高，但真正接受手术的患者人数很少，暂不足以证明P-32可以显著提高转化手术机会。
因此，TRIPP-FFX的“成功”是达到预设Ⅱ期终点并验证技术可实施性，而不是已经确立联合方案优于FOLFIRINOX。四、安全性
任意级别不良事件在两组中均接近100%，≥3级不良事件发生率分别为：
P-32联合组70.7%；
FOLFIRINOX组60.9%。
联合组中，14.6%的患者发生了研究者判断与P-32器械或植入操作相关的≥3级不良事件。其他常见严重事件包括中性粒细胞减少、腹泻、腹痛和转氨酶升高。
OncoSil的商业化门槛也不只是产品获批。其实际使用涉及：
消化内镜超声引导穿刺；核医学或放射药房制备；个体化剂量计算；
放射防护和污染管理；肿瘤内科、介入内镜及核医学多学科协作。
这意味着OncoSil的产品价值不仅取决于临床数据，还取决于中心认证、医生培训、操作标准化、支付覆盖和患者转诊能力。五、从监管角度看，TRIPP-FFX首先是一项标签扩展研究
OncoSil已经在欧洲、英国和澳大利亚获得用于不可切除局部晚期胰腺癌的相关器械准入，但获批搭配方案主要是吉西他滨类化疗。2026年5月，澳大利亚TGA批准OncoSil联合吉西他滨类化疗用于局部晚期胰腺癌。
TRIPP-FFX的直接监管意义，是为OncoSil与FOLFIRINOX联合使用提供证据。公司计划在2026年下半年向欧洲和英国相关机构提交标签变更申请。
这也是该研究在产业层面的真正价值：FOLFIRINOX是胰腺癌重要化疗骨架，若能够完成标签扩展，OncoSil的可及人群和临床使用场景将明显扩大。六、除P-32微粒外，胰腺癌还出现了哪些创新疗法？
截至2026年7月，胰腺癌创新治疗已形成多条相对清晰的技术路线。
1. RAS终于从“不可成药”走向Ⅲ期验证
胰腺导管腺癌中超过90%的肿瘤存在RAS通路驱动，KRAS G12D、G12V和G12R是主要亚型。
2026年ASCO公布的RASolute 302研究，是目前胰腺癌靶向治疗最重要的转折之一。经治转移性患者接受口服RAS(ON)多选择性抑制剂daraxonrasib后，中位OS达到13.2个月，对照化疗为6.7个月，HR为0.40。研究结果已发表于《新英格兰医学杂志》，FDA也已允许开展扩大使用计划，但截至2026年7月尚未完成正式上市批准。
在更早线治疗中，KRAS G12D选择性抑制剂zoldonrasib联合mFOLFIRINOX的ORR达到82%，联合吉西他滨/白蛋白紫杉醇的ORR为61%。但这些数据来自早期、非随机队列，仍需Ⅲ期研究验证。
RAS抑制剂的成功，将直接推动胰腺癌分子检测从“寻找少数罕见靶点”，转向影响大多数患者的治疗决策。2. 局部物理治疗不再只有传统放疗
2026年2月，FDA批准Optune Pax联合吉西他滨/白蛋白紫杉醇用于局部晚期胰腺癌。该设备通过贴在腹部的换能器持续产生150 kHz交变电场，干扰肿瘤细胞有丝分裂。
PANOVA-3研究中，中位OS为16.2个月，对照组为14.2个月，HR为0.82。
Optune Pax与OncoSil分别代表两种不同的物理治疗商业模式：
Optune Pax：无创、持续佩戴，但依从性和皮肤反应可能影响使用；
OncoSil：一次性肿瘤内植入，但依赖专业中心和介入操作。
两者共同说明，胰腺癌局部治疗正在从传统外照射放疗，向电场、核素微粒等新的物理机制扩展。3. 微环境调节重新获得临床验证机会
elraglusib是一款GSK-3β抑制剂，试图同时影响肿瘤细胞存活、化疗耐药和免疫抑制。
随机Ⅱ期研究中，elraglusib联合吉西他滨/白蛋白紫杉醇使中位OS从7.2个月延长至10.1个月，1年生存率由22.3%提高至44.1%，但仍需Ⅲ期研究确认。
考虑到PEGPH20等多款胰腺癌间质靶向药物此前折戟，elraglusib的结果为微环境调节重新提供了临床验证窗口。4. 罕见亚型开始兑现精准治疗价值
对于KRAS野生型患者，NRG1、NTRK、RET、BRAF及HER2等罕见改变具有更高检测价值。
2024年，FDA加速批准HER2×HER3双特异性抗体zenocutuzumab，用于经治NRG1融合阳性晚期胰腺腺癌，胰腺癌队列ORR约40%。虽然NRG1融合患者比例很低，但该批准证明胰腺癌并非完全无法复制肺癌的“罕见驱动基因＋精准治疗”模式。七、胰腺癌研发的竞争逻辑正在改变
过去，胰腺癌新药开发的核心问题是“能否在化疗基础上增加几个月生存期”。2026年的连续进展表明，研发竞争正在分化为三个层次：
第一，RAS抑制剂开始进入大人群、高商业价值赛道。daraxonrasib的Ⅲ期成功不只是单个产品突破，更验证了直接打击胰腺癌核心驱动机制的可行性。
第二，器械和局部治疗正在填补药物递送不足。OncoSil和Optune Pax都绕开了胰腺癌低灌注和致密间质造成的部分药物递送障碍，但商业化高度依赖患者筛选、使用便利性、中心能力和支付体系。
第三，精准治疗从少数患者中建立确定性。NRG1、BRCA/PALB2、MSI-H、NTRK和RET等人群比例有限，却可能获得显著高于平均水平的治疗收益，推动更广泛的胚系和肿瘤基因检测。结语
TRIPP-FFX达到双重主要终点，证明P-32微粒可以与FOLFIRINOX整合进局部晚期胰腺癌的治疗流程，并呈现ORR、PFS和OS方面的积极信号。但联合组没有在16周局部疾病控制率或手术切除率上形成明确优势，现阶段尚不能将其定义为新的标准治疗。
P-32微粒真正值得关注的地方，不是它已经解决了胰腺癌，而是它代表了一种新的开发逻辑：当药物难以充分进入肿瘤时，治疗可以通过放射性微粒、电场和介入技术直接作用于局部病灶；当化疗触及疗效上限时，RAS抑制、微环境调节和精准治疗开始承担新的增量价值。
胰腺癌仍然是最难突破的实体瘤之一，但其创新路径已经不再只有化疗一条线。
放射疗法临床3期临床2期临床结果
2026-07-10
点击上方
关注我们
本期主讲人：孙荣泽主治医师
出诊时间：周三下午（北院区）
转移性胰腺导管腺癌（mPDAC）恶性程度极高，传统一线GnP（白蛋白紫杉醇联合吉西他滨）化疗生存获益有限，且肿瘤致密基质、免疫抑制微环境持续制约治疗效果。Elraglusib 为全球首创GSK-3β小分子抑制剂，可靶向调控胰腺癌基质纤维化、逆转化疗耐药、重塑抗肿瘤免疫微环境。《Nature Medicine》2026年刊发的II期RCT（Actuate-1801 Part3B），首次在全球多中心人群中对比Elraglusib联合GnP与单纯GnP方案一线治疗晚期胰腺癌的生存获益、抗肿瘤活性及安全性。研究以总生存期、1年期生存率为主要终点，证实联合方案可显著延长患者生存、大幅提升1年期生存率，且不良反应整体可控；但客观缓解、无进展生存期改善幅度有限，试验设计、人群基线存在一定局限性，仍科作为III期确证研究的前置依据。本文将简述研究内容，并分析其临床价值及未来展望。
一、研究背景及方案设计
（一）研究背景
胰腺导管腺癌存在独特“纤维化屏障”，高表达 GSK-3β 激酶持续激活NF-κB、EMT通路，诱导肿瘤相关巨噬细胞浸润、抑制CD8+T细胞浸润，介导化疗耐药，是胰腺癌治疗失败核心机制。GnP方案是指南推荐mPDAC一线标准化疗方案，经典III期MPACT研究中单纯GnP治疗中位总生存期达8.5个月，但真实世界中晚期、高肿瘤负荷患者生存期普遍不足，且长期生存人群极少，临床亟需联合靶向微环境的新型药物改善这一现状。
Elraglusib是选择性GSK-3β抑制剂，临床前模型证实其可减少胰腺基质胶原沉积、降低免疫抑制细胞、恢复化疗DNA损伤杀伤效应，具备与GnP协同抗肿瘤潜力，为本次随机对照II期研究提供理论基础。
（二）试验方案
该研究为国际多中心、开放标签、随机对照II期临床试验，试验编号NCT03678883，全球60余家中心共同开展，入组周期覆盖多国晚期胰腺癌人群，总筛选入组286例初治转移性胰腺导管腺癌患者，2:1随机分层分组，分层因素包含肝转移状态、ECOG体能评分、一线治疗基线特征等。
具体分组与给药方案如下：联合组（n=191）：Elraglusib 9.3mg/kg 每周静脉输注，同步标准GnP化疗（白蛋白紫杉醇 125mg/m²、吉西他滨 1000mg/m²，第1、8、15天给药，28天为1周期）；对照组（n=95）：仅接受标准GnP化疗；改良意向治疗人群mITT为预设疗效分析集：联合组155例，对照组78例，为最终统计核心人群。同时本试验试验放宽传统筛选限制，纳入大量高CA19-9、低白蛋白、合并肝转移等高风险预后人群，更贴近真实世界临床场景。
研究终点：双主要终点：中位总生存期（mOS）、1 年总生存率；次要终点：客观缓解率ORR、疾病控制率DCR、中位无进展生存期mPFS、全维度治疗相关不良反应TRAE、长期 2 年生存比例；探索性终点：免疫生物标志物、肝转移亚组疗效、毒性特征分层分析。
二、研究核心结果
（一）生存情况改善（核心阳性终点）
数据截止2025年4月27日，mITT人群生存数据呈现显著统计学差异：中位总生存期：Elraglusib+GnP组10.1个月vs单纯GnP对照组7.2个月，中位OS延长2.9个月，死亡风险降低38%，HR=0.62，95% CI 0.46–0.84，P=0.01，达到预设主要终点；
年度生存里程碑：1年生存率联合组44.1%，对照组仅22.3%；18个月生存率20.5% vs 4.4%；2年生存率13.2%，而单纯化疗组无患者存活超过24个月，长期生存获益优势突出；高危亚组一致性获益：合并肝转移患者是胰腺癌预后最差人群，联合组mOS 8.3个月，对照组6.6 个月，HR=0.62，获益幅度与整体人群完全一致，证实药物对晚期广泛转移人群有效。
（二）肿瘤客观缓解与进展指标
客观疗效指标仅呈现改善趋势，无统计学显著差异：联合组ORR 37.9%、DCR 53.4%；对照组ORR 29.3%、DCR 44.8%；中位PFS联合组6.9个月，对照组5.6个月。该现象存在独特机制解释：Elraglusib核心作用靶点为肿瘤基质与免疫微环境，并非直接杀伤肿瘤细胞，因此短期肿瘤缩小幅度有限，但可抑制侵袭、远处转移，持续延缓疾病进展，最终转化为长期生存获益，这一特征与免疫治疗临床规律高度相似。
（三）安全性与不良反应数据
两组整体毒性谱相近，无新增致命性严重不良反应，安全性整体可控：特征性靶向相关毒性：Elraglusib特异性不良反应为一过性可逆视觉障碍，发生率超60%，多表现为视物模糊、色觉异常，给药后数天自行缓解，无永久性视力损伤，极少需要永久停药；化疗叠加毒性：联合组3级及以上中性粒细胞减少发生率52.3%，高于对照组30.8%，骨髓抑制轻度加重，其余消化道反应、乏力等传统化疗毒性无明显差异；停药率对比：两组因不良反应永久停药比例接近，无显著差异，证实联合方案耐受性未出现断崖式下降，临床可通过剂量调整、对症干预管理毒性。
三、研究临床价值与创新意义
（一）填补胰腺癌微环境靶向治疗空白
既往晚期胰腺癌一线治疗仅依靠细胞毒化疗，免疫单药、双免疫方案整体获益微弱，RAS 靶向药物目前仍用于二线RAS突变人群，缺乏一线微环境靶向联合化疗的循证证据。本研究首次通过随机对照试验证实GSK-3β抑制剂可同步改善晚期胰腺癌总生存，开辟“基质调控+传统化疗”全新治疗思路。
（二）高真实世界人群数据更具临床参考价值
区别于MPACT等经典III期试验严格筛选低负荷、体力状态佳患者，本研究纳入近20% 低白蛋白、超25%极高 CA19-9、大量肝转移高风险人群，对照组GnP中位OS 7.2个月与全球真实世界研究结果匹配。其生存获益在预后极差人群中稳定显现，相比高标准筛选临床试验，结论更贴合日常肿瘤科临床诊疗场景，对基层、晚期体弱患者治疗方案选择具备更强指导意义。
（三）揭示 “生存获益与短期缩瘤分离” 全新疗效模式
传统实体瘤药物评价体系高度依赖ORR、PFS作为疗效预判标准，本研究打破固有评价逻辑：短期肿瘤缓解无明显提升，但长期生存显著改善，证明基质免疫调控类药物存在独特获益时序。该结果为后续胰腺癌新药临床试验终点设计提供参考，提示针对微环境靶向药物，应将长期 OS、远期生存率作为核心评价指标，而非单纯依靠短期肿瘤缩小。
同时本研究作为II期试验，证据等级有限，部分研究局限仍需后续III期试验证实。生存获益仍需大型 III 期多中心研究重复验证，现阶段仅能作为探索性证据。本试验未采用双盲安慰剂对照，医患均知晓分组方案，可能影响影像学评估、患者报告症状终点判定；单纯GnP 对照组患者因无新型靶向药物，存在较高脱落率，对长期生存数据完整性造成一定干扰。另外本研究仅开展少量探索性生物标志物分析，未明确可筛选优势获益人群的分子特征，无法回答“哪些患者更适合 Elraglusib 联合方案”这一关键问题。
四、综合总结与临床展望
本研究作为GSK-3β靶点在胰腺癌领域里程碑式探索研究，试验设计贴合真实临床实践，以总生存为核心终点，清晰证实联合方案可显著延长晚期患者生存期、倍增1年生存率，在肝转移等高风险人群中获益稳定，不良反应整体可控。创新性证实基质免疫靶向联合化疗是突破晚期胰腺癌治疗瓶颈的可行路径，丰富胰腺癌全身治疗机制研究，为后续新药研发提供全新靶点方向。
同时，受限于II期试验样本规模、开放标签设计、缺乏精准预测标志物等因素，后续亟需开展III期试验确证性临床试验重复验证生存获益，并同步开发疗效生物标志物、口服剂型，进一步优化用药便捷性与个体化筛选能力。与近期在二线治疗相关研究中效果显著的RAS相关靶向药物的疗效对比或联合用药也可作为未来研究方向。
END
点赞
转发
推荐
评论
2026-07-01
Nature Medicine Volume 32 Issue 1
自然·医学 32卷 1期
https://www.nature.com/nm/volumes/32/issues/1
Nature Medicine Commission on Dialysis Policy in LMICs
《自然·医学》低收入和中等收入国家（LMICs）透析政策委员会专刊
In this issue, Teerawattananon and colleagues present policy goals and recommendations from the Nature Medicine Commission on Dialysis Policy in Low- and Middle-Income Countries (LMICs). The goal of the commission was to address current dialysis policy challenges in Thailand, and to provide lessons for other countries seeking to integrate dialysis into universal health coverage in a way that is sustainable, equitable and safe.
在本期内容中，Teerawattananon及其同事阐述了《自然·医学》低收入和中等收入国家（LMICs）透析政策委员会提出的政策目标与建议。该委员会旨在应对泰国当前在透析政策方面面临的挑战，并为其他寻求以可持续、公平且安全的方式将透析服务纳入全民健康覆盖体系的国家提供经验借鉴。
Editorial（社论）
1
Nature Portfolio Commissions: data-driven solutions to global problems
《自然》系列期刊专刊：以数据为驱动解决全球问题
The first Nature Portfolio Commission Report outlines paths to sustainable dialysis policies, robust evidence-to-policy translation and south–south collaboration.
首份《自然》系列期刊专刊报告概述了实现可持续透析政策、有力推动证据向政策转化以及开展南南合作的路径。
Collection: Nature Medicine Commission on dialysis policy in low- and middle-income countries
专题：低收入和中等收入国家《自然·医学》透析政策委员会专刊
Nature Medicine volume 32（1）, page：1 (2026)
News（新闻）
2
Is addiction the next frontier for GLP-1 receptor agonists?
GLP-1受体激动剂会是成瘾治疗领域的下一个突破口吗？
Researchers are probing whether the blockbuster drugs that transformed obesity treatment could also quiet the brain’s cravings for substances such as alcohol, nicotine and opioids.
研究人员正在探究，那些彻底改变肥胖治疗方式的重磅药物是否也能抑制大脑对酒精、尼古丁和阿片类药物等物质的渴望。
Natalie Healey
Nature Medicine volume 32（1）, pages：2-3 (2026)
Partner Content（合作内容）
Explore the next frontier in allogeneic CAR-T innovation
探索异体CAR-T创新领域的下一个前沿
Allogene is aiming to develop a first-line consolidation treatment for large B-cell lymphoma that predicts and prevents relapse.
Allogene公司旨在开发一种针对大B细胞淋巴瘤的一线巩固治疗方案，该方案可预测并预防疾病复发。
News Feature（新闻特写）
3
Silenced genomes
沉默的基因组
Projects worldwide push for more diverse genomic databases across Asia, Africa and the Americas.
全球各地的项目正推动建立涵盖亚洲、非洲和美洲的更多样化的基因组数据库。
Sofia Moutinho
Nature Medicine volume 32（1）, pages：4–8 (2026)
Turning Points（转折点）
4
Early successes in colon immunotherapy
结直肠免疫治疗的早期成功
How an exploratory study of neoadjuvant immunotherapy saved patient lives.
一项新辅助免疫治疗的探索性研究如何挽救患者生命。
Myriam Chalabi
Nature Medicine volume 32（1）, page：9 (2026)
Correspondence（读者来信）
5
The evolving landscape of cardiovascular health in Africa: insights from WHO AFRO
非洲心血管健康格局的演变：来自世卫组织非洲区域办事处的见解
Bayan GalalEeshaan MalladiMohamed Janabi
Nature Medicine volume 32（1）, pages：10–11 (2026)
6
Navigating difficult ethical decisions in global health
全球卫生领域中艰难伦理决策的应对之道
Maxwell J. SmithDiego S. SilvaKatherine Littler
Nature Medicine volume 32（1）, pages：12–13 (2026)
7
The Italian parliament first to recognize obesity as a chronic and relapsing disease
意大利议会率先承认肥胖是一种慢性复发性疾病
Silvio BuscemiMaurizio De LucaFederico Serra
Nature Medicine volume 32（1）, pages：14–15 (2026)
8
Harnessing evidence-based solutions for climate resilience and women’s, children’s and adolescents’ health
利用循证解决方案提升气候适应能力，促进妇女、儿童和青少年健康
Rajat KhoslaHelen ClarkFlavia Bustreo
Nature Medicine volume 32（1）, pages：16-17 (2026)
9
MASLD as a complication of obesity must include liver risk stratification
作为肥胖并发症的代谢障碍相关脂肪性肝病（MASLD）必须纳入肝脏风险分层管理
Mary E. RinellaArun J. SanyalVlad Ratziu
Nature Medicine volume 32（1）, pages：18–19 (2026)
10
Clarification of evidence selection for the framework for the pharmacological treatment of obesity and its complications from the EASO
欧洲肥胖研究协会（EASO）关于肥胖及其并发症药物治疗框架的证据选择说明
Andreea CiudinBarbara McGowan
Nature Medicine volume 32（1）, page：20 (2026)
World View（世界视角）
11
When science meets violence
当科学遭遇暴力
Women scientists deserve safety — not silence.
女科学家应得到安全保障，而非沉默以对。
Luana Araujo
Nature Medicine volume 32（1）, page：21 (2026)
Comment（述评）
12
Sustaining kidney failure care under universal health coverage
全民健康覆盖下维持肾衰竭治疗
Rising demand for dialysis poses a central challenge to universal health coverage systems: not just whether to expand access, but how to sustain equitable, high-quality kidney failure care. In this Comment, I argue that long-term viability depends on system architecture, rather than modality choice alone.
透析需求不断增长，给全民健康覆盖体系带来了核心挑战：不仅在于是否要扩大服务可及性，更在于如何维持公平、高质量的肾衰竭治疗。在本文评论中，我认为长期可行性取决于系统架构，而非仅依赖治疗方式的选择。
Syarifah Liza Munira
Collection: Nature Medicine Commission on dialysis policy in low- and middle-income countries
专题：低收入和中等收入国家《自然·医学》透析政策委员会专刊
Nature Medicine volume 32（1）, pages：22–24 (2026)
13
A One Health trial design to accelerate Lassa fever vaccines
加速拉沙热疫苗研发的“同一健康”试验设计
We propose an interdisciplinary framework to address the considerable challenges that are restricting the development of vaccines for zoonotic diseases with epidemic potential.
我们提出了一个跨学科框架，以应对当前限制具有流行潜力的人畜共患病疫苗开发的重大挑战。
David SimonsDeborah Watson-JonesSagan Friant
Nature Medicine volume 32（1）, pages：25–27 (2026)
14
Reduce bureaucracy in clinical trials now
立即减少临床试验中的官僚主义
Clinical trials in Europe must become far more efficient to support the needs of investigators and their patients. The way trials are designed, conducted and regulated should be attuned first and foremost to the needs of patients, to ensure timely and equitable access to safe, effective and innovative treatments.
欧洲的临床试验必须大幅提高效率，以满足研究人员及其患者的需求。临床试验的设计、实施和监管方式应首先适应患者的需求，以确保患者能够及时、公平地获得安全、有效和创新的治疗方法。
Martin DreylingSara Badreh WirströmRobin Doeswijk
Nature Medicine volume 32（1）, pages：28–30 (2026)
15
Lessons in public trust
公共信任的启示
What the organ donation system can learn from global experiences with vaccine programs.
器官捐献体系能从全球疫苗接种项目的经验中学到什么。
Heidi J. LarsonAlexander H. Toledo
Nature Medicine volume 32（1）, pages：31–33 (2026)
News & Views（新闻与观点）
16
Mapping the effects of gender-affirming sex hormone therapy
绘制性别肯定性激素治疗的效应图谱
A study uses plasma proteome analysis to illuminate systemic effects of feminizing gender-affirming hormone therapy; more research like this will inform better healthcare for transgender people and could hold insights into sex-specific immune regulation.
一项研究利用血浆蛋白质组分析揭示了女性化性别肯定激素治疗的全身效应；更多此类研究将为跨性别者提供更优质的医疗服务，并可能为性别特异性免疫调控提供见解。
Petter Brodin
Nature Medicine volume 32（1）, pages：34–35 (2026)
17
Political protests, social media use and mental well-being
政治抗议、社交媒体使用与心理健康
A large, longitudinal study shows that interpersonal conflict and excessive social media use are associated with increased levels of depression during political protests — but we should not lose sight of the wider contexts in which such protests take place.
一项大型纵向研究表明，在政治抗议期间，人际冲突和过度使用社交媒体与抑郁水平上升相关——但我们不应忽视此类抗议发生的更广泛背景。
Jon RoozenbeekIli Ma
Nature Medicine volume 32（1）, pages：36–37 (2026)
18
Mechanistic insights make cancer cachexia a targetable syndrome
机制性见解使癌症恶病质成为可治疗综合征
Two studies establish a mechanism, biomarker and therapeutic strategy for cancer cachexia, all centered around the HIF-2 pathway. The findings reframe this intractable metabolic syndrome as a pharmacologically treatable condition.
两项研究围绕HIF-2通路，确立了癌症恶病质的机制、生物标志物和治疗策略。这些发现将这种顽固的代谢综合征重新定义为可通过药物治疗的病症。
Ed ReznikMartin H. VossA. Ari Hakimi
Collection: Cancer at Nature Portfolio
专题：自然系列期刊癌症研究
Nature Medicine volume 32（1）, pages：38–39 (2026)
19
Understanding the link between atrial fibrillation and cognitive decline
理解心房颤动与认知功能下降之间的关联
A phase 3 trial shows no impact of the anticoagulant rivaroxaban on the risk of cognitive decline in individuals with atrial fibrillation and low thromboembolic risk — highlighting the need for a better understanding of the mechanisms that link these conditions.
一项3期试验显示，抗凝药物利伐沙班对心房颤动且血栓栓塞风险较低患者的认知功能下降风险无影响——这凸显了进一步理解这两种病症之间关联机制的必要性。
Marco ProiettiGiulio Francesco Romiti
Nature Medicine volume 32（1）, pages：40–41 (2026)
Research Briefings（研究简报）
20
Serum biomarker enables diagnosis and monitoring of idiopathic pulmonary arterial hypertension
血清生物标志物助力特发性肺动脉高压的诊断与监测
We have identified serum levels of extracellular domain of NOTCH3 (NOTCH3-ECD) as a biomarker that can reliably distinguish idiopathic pulmonary arterial hypertension from other forms of pulmonary hypertension and healthy controls. Our findings show that serum NOTCH3-ECD levels are as accurate as current standard-of-care clinical tests in predicting disease progression and mortality risk.
我们已确定NOTCH3胞外域（NOTCH3-ECD）的血清水平可作为可靠区分特发性肺动脉高压与其他类型肺动脉高压及健康对照者的生物标志物。我们的研究结果显示，血清NOTCH3-ECD水平在预测疾病进展和死亡风险方面与当前临床标准检测同样准确。
Nature Medicine volume 32（1）, pages：42–43 (2026)
Policy Brief（政策简报）
21
The path to safe, equitable and sustainable dialysis provision for people with chronic kidney disease
为慢性肾脏病患者提供安全、公平且可持续的透析服务之路
An abrupt policy change in 2022 — allowing patients to choose between peritoneal dialysis or hemodialysis — created severe unintended consequences for the Thai health system. A multidisciplinary commission found that interacting factors in the system were overlooked and that future dialysis policies must integrate more-diverse evidence and stakeholder views, prioritizing care quality and ethics while balancing equity and sustainability.
2022年，泰国一项突发的政策变更——允许患者在腹膜透析和血液透析之间做出选择——给泰国卫生系统带来了严重的意外后果。一个多学科委员会发现，系统中的相互作用因素被忽视，未来的透析政策必须整合更多样化的证据和利益相关者的观点，在平衡公平性与可持续性的同时，将护理质量和伦理置于优先地位。
Yot TeerawattananonKinanti Khansa ChavarinaWirun Limsawart
Collection: Nature Medicine Commission on dialysis policy in low- and middle-income countries
专题：低收入和中等收入国家《自然·医学》透析政策委员会专刊
Nature Medicine volume 32（1）, pages：44–46 (2026)
Review Articles（综述）
22
The expanding landscape of GLP-1 medicines
胰高血糖素样肽-1（GLP-1）药物领域的不断拓展
This Review discusses the expansion of glucagon-like peptide-1 (GLP-1) medicines beyond type 2 diabetes and obesity, outlining opportunities for new indications, key questions around benefits and long-term safety, and areas of uncertainty requiring further research.
本综述探讨了胰高血糖素样肽-1（GLP-1）药物在2型糖尿病和肥胖症之外的应用拓展，阐述了新适应症的机遇、围绕获益和长期安全性的关键问题，以及需要进一步研究的不确定性领域。
Daniel J. Drucker
Nature Medicine volume 32（1）, pages：47–57 (2026)
Commission Report（委员会报告）
23
Nature Medicine Commission on dialysis policy in low- and middle-income countries
低收入和中等收入国家《自然·医学》透析政策委员会报告
This Commission aims to resolve the current dialysis policy challenges in Thailand and generate lessons for the global kidney community by drawing on empirical evidence, systems thinking and multidisciplinary expertise to generate policy goals and recommendations.
本委员会旨在通过借鉴实证证据、系统思维和多学科专业知识，制定政策目标和建议，解决泰国当前透析政策面临的挑战，并为全球肾脏病领域提供经验教训。
Yot TeerawattananonKinanti Khansa ChavarinaYot Teerawattananon
Collection: Nature Medicine Commission on dialysis policy in low- and middle-income countries
专题：低收入和中等收入国家《自然·医学》透析政策委员会专刊
Nature Medicine volume 32（1）, pages：58–71 (2026)
Articles（论著）
24
Genetic architecture and phenotypic diversity of oocyte and early embryo competence defects in female infertility
女性不孕症中卵母细胞和早期胚胎发育潜能缺陷的遗传结构与表型多样性
Whole-exome sequencing analyses in a cohort of 2,140 participants with female infertility after recurrent in vitro fertilization, coupled with functional analyses, identified genes associated with oocyte and early embryo competence defects.
对2140例反复体外受精后女性不孕症患者进行全外显子组测序分析，并结合功能分析，确定了与卵母细胞和早期胚胎发育潜能缺陷相关的基因。
Changlong ZhangWei ZhengZi-Jiang Chen
Nature Medicine volume 32（1）, pages：72–81 (2026)
25
MRI-based multi-organ clocks for healthy aging and disease assessment
基于磁共振成像（MRI）的多器官时钟用于健康衰老和疾病评估
A new study combines MRI data with proteomic, metabolomic and RNA data to develop and examine seven organ-specific MRI-based aging clocks, uncovering links to overall mortality and organ-specific diseases.
一项新研究结合磁共振成像数据与蛋白质组学、代谢组学和RNA数据，开发并检验了七种基于磁共振成像的器官特异性衰老时钟，揭示了其与总死亡率和器官特异性疾病的关联。
Huizi CaoZhiyuan SongJunhao Wen
Nature Medicine volume 32（1）, pages：82–92 (2026)
26
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials
B型血友病的IX因子-帕多瓦腺相关病毒（AAV）基因疗法：1/2期和3期临床试验
A phase 1/2 and a phase 3 trial testing an AAV-FIX Padua gene therapy in patients with hemophilia B in China showed that the treatment was well tolerated and effective in reducing the annualized bleeding rate.
在中国B型血友病患者中开展的一项1/2期和一项3期试验，对一种AAV-FIX帕多瓦基因疗法进行了测试，结果显示该疗法耐受性良好，能有效降低年出血率。
Feng XueMankai JuLei Zhang
Nature Medicine volume 32（1）, pages：93–102 (2026)
27
Oral splicing modulator branaplam in Huntington’s disease: a phase 2 randomized controlled trial
口服剪接调控剂布兰纳普兰治疗亨廷顿病：一项2期随机对照试验
Early results from the phase2b VIBRANT-HD trial of the oral splicing modulator branaplam in Huntington’s disease suggested reduced cerebrospinal fluid huntingtin levels, but safety monitoring revealed signs of peripheral neurotoxicity, prompting early termination of the study.
口服剪接调控剂布兰纳普兰治疗亨廷顿病的2b期VIBRANT-HD试验的早期结果显示，脑脊液中亨廷顿蛋白水平降低，但安全性监测发现存在周围神经毒性迹象，促使研究提前终止。
Beth BorowskyHarry RamosBlair R. Leavitt
Nature Medicine volume 32（1）, pages：103–112 (2026)
28
Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions
通过脂肪组织-微生物组相互作用对代谢性肥胖进行多组学定义
Metabolomics, metagenomics, proteins and genetics were combined with clinical data to define a metabolic signature of obesity.
将代谢组学、宏基因组学、蛋白质组学和遗传学与临床数据相结合，定义了肥胖的代谢特征。
Rima M. ChakarounMeenakshi PradhanFredrik Bäckhed
Nature Medicine volume 32（1）, pages：113–125 (2026)
29
The global macroeconomic burden of diabetes mellitus
糖尿病的全球宏观经济负担
An analysis of 204 countries estimates that diabetes will cost the global economy $10.2 trillion between the years 2020 and 2050.
一项对204个国家的分析估计，2020年至2050年间，糖尿病将给全球经济造成10.2万亿美元的损失。
Simiao ChenZhong CaoDavid E. Bloom
Nature Medicine volume 32（1）, pages：126–138 (2026)
30
Plasma proteome adaptations during feminizing gender-affirming hormone therapy
女性化性别肯定激素治疗期间的血浆蛋白质组适应性变化
Researchers analyzed 5,279 plasma proteins in 40 people undergoing feminizing gender-affirming hormone therapy over 6months, revealing significant changes in 299 proteins. Such changes could have implications for reproductive capacity, immune regulation and long-term health.
研究人员对40名接受6个月女性化性别肯定激素治疗者的5279种血浆蛋白质进行了分析，发现299种蛋白质发生了显著变化。这些变化可能对生殖能力、免疫调节和长期健康产生影响。
Nhi N. L. NguyenDen CelestraBoris Novakovic
Nature Medicine volume 32（1）, pages：139–150 (2026)
31
Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial
Elebsiran联合聚乙二醇干扰素α（PEG-IFNα）治疗慢性乙型肝炎病毒感染：一项部分随机、开放标签的2期试验
Elebsiran plus PEG-IFNα improved hepatitis B surface antigen (HBsAg) loss rates compared with PEG-IFNα alone in patients with chronic hepatitis B virus infection. Furthermore, prior response to the BRII-179 vaccine was associated with higher HBsAg clearance, suggesting its potential as a predictive tool for identifying patients more likely to benefit from therapies.
与单独使用聚乙二醇干扰素α相比，Elebsiran联合聚乙二醇干扰素α可提高慢性乙型肝炎病毒感染患者的乙型肝炎表面抗原（HBsAg）清除率。此外，先前对BRII-179疫苗有应答与更高的HBsAg清除率相关，这表明该疫苗有望成为识别更可能从治疗中获益患者的预测工具。
Grace Lai-Hung WongMan-Fung YuenZhi Hong
Nature Medicine volume 32（1）, pages：151–159 (2026)
32
Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial
通过人工智能心电图检测未确诊的肝硬化：一项实用、整群随机临床试验
In a trial involving 45 clinics and 15,596 visits, the use of an AI-based screening tool applied to ECG for opportunistic detection of advanced chronic liver disease led to a significant increase in new diagnoses compared to the standard workflow.
在一项涉及45家诊所和15596次就诊的试验中，使用基于人工智能的心电图筛查工具对晚期慢性肝病进行机会性检测，与标准工作流程相比，新诊断病例显著增加。
Douglas A. SimonettoDavid RushlowVijay H. Shah
Nature Medicine volume 32（1）, pages：160–167 (2026)
33
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
卡博特韦和利匹韦林治疗非洲HIV感染：3b期随机、开放标签、非劣效性CARES试验第96周结果
In this follow-up study presenting results at 96weeks, cabotegravir and rilpivirine long-acting therapy remained noninferior to oral therapy, had acceptable safety and tolerability profiles, and resulted in durable virologic suppression, further supporting its consideration for African treatment programs.
在这项随访研究中展示了第96周的结果，卡博特韦和利匹韦林长效疗法仍不劣于口服疗法，具有可接受的安全性和耐受性，并能实现持久的病毒学抑制，这进一步支持了将其纳入非洲治疗方案的考虑。
Cissy KityoIvan K. MambuleVeerle Van Eygen
Nature Medicine volume 32（1）, pages：168–177 (2026)
34
Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial
疟疾疫苗对皮内或静脉注射寄生虫的保护作用：一项随机2b期人体挑战试验
The R21/Matrix-M vaccine, but not the ME-TRAP vaccine, was protective against intradermal challenge with Plasmodium falciparum sporozoites, while neither was protective against direct venous inoculation, potentially explaining previously observed differences in protection.
R21/Matrix-M疫苗（而非ME-TRAP疫苗）对恶性疟原虫子孢子皮内注射挑战具有保护作用，而两种疫苗对直接静脉注射均无保护作用，这可能解释了先前观察到的保护差异。
Melissa C. KapuluFrancesca OrengePhilip Bejon
Nature Medicine volume 32（1）, pages：178–185 (2026)
35
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome
口服纯化微生物组疗法对胃肠道微生物组的影响
An exploratory analysis of the phase 3 ECOSPOR III trial shows that a higher dosage of the oral microbiome therapeutic VOWST led to enhanced pharmacokinetics, increased species engraftment and altered microbiome and metabolite profiles, providing mechanistic insights into how it may prevent Clostridioides difficile infection recurrence.
对3期ECOSPOR III试验的一项探索性分析显示，较高剂量的口服微生物组疗法VOWST可增强药代动力学，增加物种植入，并改变微生物组和代谢物谱，为该疗法如何预防艰难梭菌感染复发提供了机制见解。
Jessica A. BryantMarin VulićMatthew R. Henn
Nature Medicine volume 32（1）, pages：186–196 (2026)
36
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study
1990 - 2023年全球、区域和国家慢性呼吸系统疾病负担及新冠肺炎疫情的影响：一项全球疾病负担研究
Estimates from the Global Burden of Disease study reveal declines in chronic respiratory disease mortality between 1990 and 2023—especially during the COVID-19 pandemic—but the burdens on people affected remain substantial.
全球疾病负担研究的估计结果显示，1990年至2023年间慢性呼吸系统疾病死亡率有所下降，尤其是在新冠肺炎疫情期间，但受影响人群的负担仍然沉重。
Jiyeon OhSoeun KimDong Keon Yon
Nature Medicine volume 32（1）, pages：197–223 (2026)
37
Interpersonal conflicts, social media use and depression associated with protests
抗议活动期间的人际冲突、社交媒体使用与抑郁
A 15-year prospective cohort study found that during times of social unrest in Hong Kong, people experienced more conflicts with family and friends and this coincided with the use of social media—these factors were also associated with higher levels of depression.
一项为期15年的前瞻性队列研究发现，在香港社会动荡时期，人们与家人和朋友的冲突增多，这与社交媒体的使用同时发生，这些因素也与更高的抑郁水平相关。
Jian ShiCandi M. C. LeungMichael Y. Ni
Nature Medicine volume 32（1）, pages：224–230 (2026)
38
AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer
基于组织病理学的人工智能虚拟空间蛋白质组学用于肺癌可解释生物标志物发现
A model trained to generate spatial proteomics profiles and predict the expression of 40 biomarkers directly from histopathology slides is shown to improve survival and treatment response prediction in patients with lung cancer.
一项训练模型可直接从组织病理学切片生成空间蛋白质组学图谱并预测40种生物标志物的表达，该模型可改善肺癌患者的生存和治疗反应预测。
Zhe LiYuchen LiRuijiang Li
Nature Medicine volume 32（1）, pages：231–244 (2026)
39
Targeting of HIF2-driven cachexia in kidney cancer
针对肾癌中HIF2驱动的恶病质
In vivo experiments and clinical cohort analyses show that hypoxia-inducible factor2 (HIF2)-induced parathyroid hormone-related protein (PTHrP) expression contributes to cachexia in the context of renal cell carcinoma (RCC). The pathway can be targeted by HIF2 inhibitors, including belzutifan, which may reduce cachexia in patients with RCC.
体内实验和临床队列分析表明，在肾细胞癌（RCC）背景下，缺氧诱导因子2（HIF2）诱导的甲状旁腺激素相关蛋白（PTHrP）表达会导致恶病质。该通路可通过包括贝组替凡（belzutifan）在内的HIF2抑制剂进行靶向治疗，这可能减轻肾细胞癌患者的恶病质症状。
Muhannad Abu-RemailehLaura A. StranskyWilliam G. Kaelin Jr
Nature Medicine volume 32（1）, pages：245–257 (2026)
40
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial
针对胰腺癌的自体多抗原靶向T细胞疗法：一项1/2期试验
Results of the phase 1/2 TACTOPS trial show that autologous T cell therapy targeting PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1 in patients with pancreatic ductal adenocarcinoma is feasible and safe, and leads to encouraging clinical responses and evidence of antigen spreading in responders.
1/2期TACTOPS试验结果显示，针对PRAME、SSX2、MAGEA4、Survivin和NY-ESO-1的自体T细胞疗法在胰腺导管腺癌患者中可行且安全，并能带来令人鼓舞的临床反应，且在有反应的患者中观察到抗原扩散的证据。
Benjamin L. MusherSpyridoula VasileiouAnn M. Leen
Nature Medicine volume 32（1）, pages：258–269 (2026)
41
Immune profiling in a living human recipient of a gene-edited pig kidney
基因编辑猪肾活体受者的免疫图谱分析
High-dimensional immune profiling of a living recipient of a pig-to-human xenotransplant provides insight into the immune landscape of xenotransplantation and directions for improved immunosuppression strategies.
对猪到人异种移植活体受者进行的高维免疫图谱分析，为了解异种移植的免疫格局以及改进免疫抑制策略提供了见解。
Guilherme T. RibasAndré F. CunhaLeonardo V. Riella
Nature Medicine volume 32（1）, pages：270–280 (2026)
42
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure
白蛋白尿作为肾衰竭替代终点的荟萃分析
In a meta-analysis of 48 randomized trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting the use of albuminuria change as a surrogate endpoint in clinical trials for chronic kidney disease.
一项针对48项慢性肾脏病进展随机试验的荟萃分析显示，6个月尿白蛋白与肌酐比值降低与已确立的肾脏病终点事件风险比降低相关，这支持将白蛋白尿变化作为慢性肾脏病临床试验的替代终点。
Hiddo J. L. HeerspinkWillem H. CollierLesley A. Inker
Nature Medicine volume 32（1）, pages：281–287 (2026)
43
Generative AI-based low-dose digital subtraction angiography for intra-operative radiation dose reduction: a randomized controlled trial
基于生成式人工智能的低剂量数字减影血管造影用于术中辐射剂量降低：一项随机对照试验
A model, trained to generate synthetic, patient-specific angiography images, reduced radiation exposure to patients and clinicians by two-thirds in a multicenter randomized controlled trial involving 1,068 patients.
在一项涉及1068例患者的多中心随机对照试验中，训练用于生成合成、患者特异性血管造影图像的模型，将患者和临床医生的辐射暴露量降低了三分之二。
Huangxuan ZhaoYaowei BaiChuansheng Zheng
Nature Medicine volume 32（1）, pages：288–296 (2026)
44
Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
抗凝治疗预防心房颤动患者缺血性脑卒中和神经认知障碍：BRAIN-AF随机临床试验
In a multicenter, randomized trial of patients with atrial fibrillation and a low risk of thromboembolic events, treatment with the anticoagulant rivaroxaban showed no benefit in reducing cognitive decline, stroke or transient ischemic attack when compared to placebo.
在一项针对低血栓栓塞事件风险心房颤动患者的多中心随机试验中，与安慰剂相比，使用抗凝剂利伐沙班治疗在减少认知功能下降、脑卒中或短暂性脑缺血发作方面未显示出益处。
Léna RivardPaul KhairyWilliam Liang
Nature Medicine volume 32（1）, pages：297–305 (2026)
45
The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension
NOTCH3胞外域是肺动脉高压的血清生物标志物
A protein biomarker, the NOTCH3 extracellular domain, identifies individuals with idiopathic pulmonary hypertension, correlates with disease progression, improves mortality risk prediction and provides a readily implementable, noninvasive blood test for this disease.
一种蛋白质生物标志物——NOTCH3胞外域，可识别特发性肺动脉高压患者，与疾病进展相关，能改善死亡风险预测，并为该疾病提供了一种易于实施的非侵入性血液检测方法。
Moises HernandezNolan M. WinickiPatricia A. Thistlethwaite
Nature Medicine volume 32（1）, pages：306–317 (2026)
46
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial
血流储备分数指导的经皮冠状动脉介入治疗与药物治疗稳定型冠状动脉疾病：FAME 2试验的长期结果
In a long-term follow-up of the FAME2 trial, fractional flow reserve-guided percutaneous coronary intervention plus medical therapy in patients with stable coronary artery disease reduced cardiovascular events compared to medical therapy alone, primarily due to a decrease in urgent revascularization events.
在FAME 2试验的长期随访中，对于稳定型冠状动脉疾病患者，血流储备分数指导的经皮冠状动脉介入治疗联合药物治疗与单纯药物治疗相比，可减少心血管事件，这主要归因于紧急血运重建事件的减少。
Carlos ColletThabo MahendiranPeter Jüni
Nature Medicine volume 32（1）, pages：318–324 (2026)
47
Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction
射血分数轻度降低或保留的心力衰竭综合药物治疗的终身获益
In a cross-trial analysis, combined treatment with medications that have individually shown to improve cardiovascular outcomes in heart failure with mildly reduced or preserved ejection fraction demonstrates substantial benefit, including for event-free survival.
一项跨试验分析显示，对于射血分数轻度降低或保留的心力衰竭，联合使用单独显示可改善心血管结局的药物可带来显著益处，包括无事件生存期延长。
Muthiah VaduganathanBrian L. ClaggettScott D. Solomon
Nature Medicine volume 32（1）, pages：325–331 (2026)
48
Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial
基于内型分型的疗法治疗无阻塞性冠状动脉疾病且伴有胸痛的患者：一项随机试验
As presented at the American Heart Association Conference 2025, patients with chest pain and without obstructive coronary artery disease benefit from treatment informed by cardiovascular magnetic resonance.
如2025年美国心脏协会会议所展示，对于无阻塞性冠状动脉疾病且伴有胸痛的患者，基于心血管磁共振的内型分型指导治疗可带来益处。
Conor P. BradleyGemma McKinleyColin Berry
Nature Medicine volume 32（1）, pages：332–341 (2026)
49
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice
司美格鲁肽和替西帕肽对临床实践中2型糖尿病患者心血管预后的影响
As presented at AHA Scientific Sessions 2025, in a trial emulation analysis including benchmarking to data from randomized clinical trials, treatment with semaglutide and tirzepatide showed similar levels of benefit on cardiovascular outcomes in individuals at elevated cardiovascular risk with obesity and diabetes.
如2025年美国心脏协会科学会议上所展示，在一项包含与随机临床试验数据进行基准对比的试验模拟分析中，对于肥胖且患糖尿病、心血管风险升高的个体，司美格鲁肽和替西帕肽治疗在心血管预后方面显示出相似的获益水平。
Nils KrügerSebastian SchneeweissShirley V. Wang
Nature Medicine volume 32（1）, pages：342–352 (2026)
50
Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial
利拉鲁肽治疗轻中度阿尔茨海默病：一项2b期临床试验
Results from the phase ELAD 2 trial reveal that liraglutide is safe and well tolerated in people with mild to moderate Alzheimer’s disease but does not significantly slow brain metabolism decline.
ELAD 2期试验结果显示，利拉鲁肽在轻中度阿尔茨海默病患者中安全且耐受性良好，但未能显著减缓脑代谢下降速度。
Paul EdisonGrazia Daniela FemminellaClive Ballard
Nature Medicine volume 32（1）, pages：353–361 (2026)
51
Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis
在多发性硬化症中，髓鞘损伤早于轴突损伤和症状发作
Myelin damage in multiple sclerosis can be detected up to 7years before symptoms, with early immune pathway activation and a 21-protein panel showing promise for presymptomatic diagnosis.
在多发性硬化症中，髓鞘损伤最早可在症状出现前7年被检测到，早期免疫通路激活以及由21种蛋白质组成的检测面板在症状前诊断方面显示出潜力。
Ahmed AbdelhakGabriel CeronoAri J. Green
Nature Medicine volume 32（1）, pages：362–368 (2026)
52
Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial
迷走神经介导的神经免疫调节治疗类风湿关节炎：一项关键随机对照试验
An implantable vagus nerve-targeted device safely reduces disease activity and joint damage in rheumatoid arthritis, offering a new nondrug treatment for patients who do not respond to or cannot tolerate medication.
一种可植入的针对迷走神经的装置可安全地降低类风湿关节炎的疾病活动度和关节损伤，为对药物无反应或无法耐受药物的患者提供了一种新的非药物治疗方法。
John R. P. TesserAngela R. CrowleyDavid Chernoff
Nature Medicine volume 32（1）, pages：369–378 (2026)
Amendments & Corrections（修订与更正）
53
Author Correction: The cold-induced lipokine 12,13-diHOME promotes fatty acid transport into brown adipose tissue
作者更正：冷诱导脂质因子12,13-二羟基十八碳烯酸促进脂肪酸向棕色脂肪组织的转运
Matthew D LynesLuiz O LeiriaYu-Hua Tseng
Nature Medicine volume 32（1）, page：379 (2026)
54
Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
作者更正：组蛋白甲基转移酶EZH2缺失导致急性髓系白血病对多种药物产生耐药性
Stefanie GöllnerThomas OellerichCarsten Müller-Tidow
Nature Medicine volume 32（1）, page：380 (2026)
Nature Medicine volume 32 Issue 2
自然医学 32卷 2期
https://www.nature.com/nm/volumes/32/issues/2
Editorial（社论）
1
Neurodegenerative diseases need more mechanism-informed trials
神经退行性疾病需要更多基于机制的研究试验
Nature Medicine volume 32（2）, page381
News（新闻）
2
Biting back at Lyme disease
反击莱姆病
Mike May
Nature Medicine volume 32（2）, pages382-383
News Feature（新闻特写）
3
Fault lines in a global promise
全球承诺中的裂痕
Paul Adepoju
Nature Medicine volume 32（2）, pages384–387
Correspondence（读者来信）
4
The Translational Research and Innovation Laboratory (TRAIL) model for accelerating discovery through a shared institutional resource
通过共享机构资源加速发现：转化研究与创新实验室（TRAIL）模式
Steven BruzekGrant VestalNeil Goldenberg
Nature Medicine volume 32（2）, pages388–389
5
Disentangling climate hazards from demographic change in climate–health projections
在气候与健康预测中厘清气候灾害与人口变化的影响
Josiah L. KephartUsama Bilal
Nature Medicine volume 32（2）, pages390–391
6
China’s evidence-based re-evaluation of traditional Chinese medicine injections
中国对中药注射剂基于证据的重新评估
Chen ChenZiwei Hou
Nature Medicine volume 32（2）, pages392–393
7
Reorienting Ebola care toward human-centered sustainable practice
将埃博拉护理转向以人为本的可持续实践
Richard Kitenge OmasumbuLuca FontanaMory Keita
Nature Medicine volume 32（2）, pages394–395
8
Lessons from Rwanda’s response to the Marburg virus outbreak
卢旺达应对马尔堡病毒爆发的经验教训
Sabin NsanzimanaYvan ButeraTsion Firew
Nature Medicine volume 32（2）, pages396–397
World View（国际视野）
9
US vaccine policy must put America first
美国疫苗政策必须将美国置于首位
Angela L. Rasmussen
Nature Medicine volume 32（2）, pages398-399
Comment（述评）
10
Building a code of conduct for AI-driven clinical consultations
制定人工智能驱动临床咨询的行为准则
Ernest LimArun ThirunavukarasuIbrahim Habli
Nature Medicine volume 32（2）, pages400–403
11
How to interpret ‘zero-shot’ results from generative EHR models
如何解读生成式电子健康记录模型的“零样本”结果
Suhana BediJason Alan FriesNigam H. Shah
Nature Medicine volume 32（2）, pages404–406
12
The ethics of multi-cancer screening
多癌种筛查的伦理问题
Thomas CallenderAnne MackieAnne-Marie Slowther
Nature Medicine volume 32（2）, pages407–409
13
Identifying ultra-processed foods for policy
为制定政策定义超加工食品
Alyssa J. MoranNeha KhandpurChristina A. Roberto
Nature Medicine volume 32（2）, pages410–413
News & Views（新闻与观点）
14
Housing modifications for heat adaptation
用以适应高温的房屋改造
Salum MshamuLorenz von SeidleinJakob Brandberg Knudsen
Nature Medicine volume 32（2）, pages414–415
15
Placebo effect influences vaccine responses
安慰剂效应影响疫苗反应
Kyungdeok KimBen TitleJonathan Kipnis
Nature Medicine volume 32（2）, pages416–417
16
Practical solutions to weight management in primary care
初级医疗保健中体重管理的实用解决方案
Nerys AstburyElizabeth Morris
Nature Medicine volume 32（2）, pages418–419
17
Going beyond genomics in precision oncology
精准肿瘤学正在超越基因组学
Irene PaassenMark A. Rubin
Nature Medicine volume 32（2）, pages420–422
Research Briefings（研究简报）
18
Integration of health check-ups into school and healthcare systems can improve adolescent health in LMICs
将健康检查纳入学校和医疗保健系统可改善中低收入国家青少年的健康状况
Nature Medicine volume 32（2）, pages423–424
19
PD-1 blockade reprograms antiviral immunity and reduces the HIV reservoir
PD-1阻断可重编码抗病毒免疫并减少HIV储存库
Nature Medicine volume 32（2）, pages425–426
20
A low-toxicity linezolid analog has potential for use in all patients with tuberculosis
一种低毒性的利奈唑胺类似物有潜力用于所有结核病患者
Nature Medicine volume 32（2）, pages427–428
21
Capillary blood sampling for detecting biomarkers of Alzheimer’s disease
利用毛细血管采血检测阿尔茨海默病生物标志物
Nature Medicine volume 32（2）, pages429–430
22
Immune cells in circulation serve as living biomarkers for inflammatory diseases
循环中的免疫细胞可作为炎症性疾病的活体生物标志物
Nature Medicine volume 32（2）, pages431–432
23
Large-scale analysis identifies metabolites associated with type 2 diabetes
大规模分析确定与2型糖尿病相关的代谢物
Nature Medicine volume 32（2）, pages433–434
24
Clinically relevant variants from the Mexican biobank show striking diversity across Hispanic people
来自墨西哥生物样本库的临床相关变异在西班牙裔人群中呈现出惊人的多样性
Nature Medicine volume 32（2）, pages435–436
25
Blood biomarkers reveal pathways associated with multimorbidity
血液生物标志物揭示与多种共病相关的通路
Nature Medicine volume 32（2）, pages437–438
Perspectives（观点）
26
Scaling medical AI across clinical contexts
跨临床场景扩展医学人工智能应用规模
Michelle M. LiBen Y. ReisMarinka Zitnik
Nature Medicine volume 32（2）, pages439–448
Review Articles（综述）
27
The science of psychedelic medicine
迷幻药医学的科学研究
Joshua S. SiegelConor ListonMichael P. Bogenschutz
Nature Medicine volume 32（2）, pages449–462
Matters Arising（待议问题）
28
Concerns over conclusions in an ultra-processed food trial
对一项超加工食品试验结论的担忧
David S. LudwigWalter C. WillettMary E. Putt
Nature Medicine volume 32（2）, pages463–464
29
Concerns around evidence that food processing should be included in dietary guidance
对将食品加工纳入膳食指南这一证据的质疑
Eric RobinsonCiarán G. Forde
Nature Medicine volume 32（2）, pages465–467
30
Concerns about attributing weight change to processing in a crossover feeding trial
对一项交叉喂养试验中将体重变化归因于食品加工的担忧
Zixuan WangCan Peng
Nature Medicine volume 32（2）, pages468–469
31
Reply to Ludwig, D. S. et al.; Robinson, E. & Forde, C. G.; Wang, Z. & Peng, C.
对Ludwig, D. S.等人、Robinson, E. & Forde, C. G.、Wang, Z. & Peng, C.的回复
Samuel J. DickenAdrian BrownRachel L. Batterham
Nature Medicine volume 32（2）, pages470–471
Brief Communications（简讯）
32
Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy
腺相关病毒基因治疗后肝脏中出现污染性质粒序列和被破坏的载体基因组
Sarah BuddleLi-An K. BrownJudith Breuer
Nature Medicine volume 32（2）, pages472–480
Articles（论著）
33
Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial
在未接受治疗的脊髓性肌萎缩症患者中鞘内注射onasemnogene abeparvovec：一项3期随机对照试验
Crystal M. ProudDũng ChíVũYuh-Jyh Jong
Nature Medicine volume 32（2）, pages481–487
34
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial
在已接受治疗的脊髓性肌萎缩症患者中鞘内注射onasemnogene abeparvovec：一项3b期开放标签试验
Jennifer M. KwonFrancina MunellW. Ludo van der Pol
Nature Medicine volume 32（2）, pages488–493
35
Implementation and evaluation of the Y-Check comprehensive adolescent health check-up intervention in Zimbabwe: a pre−post mixed-methods study
在津巴布韦实施并评估Y-Check综合青少年健康检查干预措施：一项前后混合方法研究
Aoife M. DoyleFarirai NzvereRashida A. Ferrand
Nature Medicine volume 32（2）, pages494–504
36
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy
抗PD-1疗法后与HIV储存库衰减相关的天然抗病毒和免疫功能
Aarthi TallaJoao L. L. C. AzevedoRafick-Pierre Sekaly
Nature Medicine volume 32（2）, pages505–517
37
Housing modifications for heat adaptation, thermal comfort and malaria vector control in rural African settlements
在非洲农村定居点进行房屋改造以适应高温、提高热舒适度并控制疟疾媒介
Bernard Abong’oDaniel KwaroMartina Anna Maggioni
Nature Medicine volume 32（2）, pages518–526
38
Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
1990 - 2023年全球204个国家安非他明、大麻、可卡因和阿片类药物使用负担：一项全球疾病负担研究
Jiseung KangHyeon Jin KimDong Keon Yon
Nature Medicine volume 32（2）, pages527–544
39
Estimating the number of incorrect tuberculosis diagnoses in low- and middle-income countries
估算中低收入国家结核病误诊数量
Ana van Lieshout TitanPeter J. DoddNicolas A. Menzies
Nature Medicine volume 32（2）, pages545–552
40
Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis
发现并开发一种用于治疗结核病的低毒性新型恶酮类药物
Brendan M. CrowleyHelena I. BoshoffDavid B. Olsen
Nature Medicine volume 32（2）, pages553–560
41
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial
儿童用减毒活基孔肯雅疫苗：一项随机2期试验
Petronela WeisováSusanne ScheiblauerJuan Carlos Jaramillo
Nature Medicine volume 32（2）, pages561–571
42
Upregulation of reward mesolimbic activity and immune response to vaccination: a randomized controlled trial
奖励性中脑边缘系统活动上调与疫苗接种免疫反应：一项随机对照试验
Nitzan LubianikerTamar KorenTalma Hendler
Nature Medicine volume 32（2）, pages572–581
43
External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial
对患有注意力缺陷多动障碍的青少年进行外部三叉神经刺激：一项随机、假对照、2b期试验
Aldo Alberto ContiNatali BozhilovaKatya Rubia
Nature Medicine volume 32（2）, pages582–590
44
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial
针对重度抑郁症的短效迷幻药干预措施：一项IIa期随机安慰剂对照试验
David ErritzoeTommaso BarbaEllen James
Nature Medicine volume 32（2）, pages591–598
45
A minimally invasive dried blood spot biomarker test for the detection of Alzheimer’s disease pathology
一种用于检测阿尔茨海默病病理学的微创干血斑生物标志物检测方法
Hanna HuberLaia Montoliu-GayaNicholas J. Ashton
Nature Medicine volume 32（2）, pages599–608
46
Reliability of LLMs as medical assistants for the general public: a randomized preregistered study
大语言模型作为面向普通大众的医疗助手时的可靠性：一项随机预注册研究
Andrew M. BeanRebecca Elizabeth PayneAdam Mahdi
Nature Medicine volume 32（2）, pages609–615
47
A large language model for complex cardiology care
用于复杂心脏病护理的大语言模型
Jack W. O’SullivanAnil PalepuTao Tu
Nature Medicine volume 32（2）, pages616–623
48
Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial
急性冠状动脉综合征低剂量白细胞介素-2抗炎治疗：一项随机2期试验
Rouchelle S. Sriranjan-RothwellTian X. ZhaoLeanne Masters
Nature Medicine volume 32（2）, pages624–632
49
Interpretable inflammation landscape of circulating immune cells
循环免疫细胞可解释的炎症特征
Laura Jiménez-GraciaDavide MasperoHolger Heyn
Nature Medicine volume 32（2）, pages633–644
50
Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial
初级医疗保健以体重管理为优先的护理流程的实施及有效性：一项阶梯式整群随机试验
Leigh PerreaultQing PanJodi Summers Holtrop
Nature Medicine volume 32（2）, pages645–652
51
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial
替西帕肽对阻塞性睡眠呼吸暂停相关心代谢风险的影响：SURMOUNT-OSA随机试验的次要结局
Atul MalhotraRonald GrunsteinJosef Bednarik
Nature Medicine volume 32（2）, pages653–659
52
Circulating metabolites, genetics and lifestyle factors in relation to future risk of type 2 diabetes
循环代谢物、遗传因素和生活方式因素与未来2型糖尿病风险的关系
Jun LiJie HuQibin Qi
Nature Medicine volume 32（2）, pages660–670
53
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
可溶性黏膜地址素细胞黏附分子-1作为转移性肾细胞癌的生物标志物
Carolina Alves Costa SilvaMarc MachaalaniLaurence Albiges
Nature Medicine volume 32（2）, pages671–681
54
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
瑞普替尼治疗NTRK融合阳性晚期实体瘤：一项1/2期试验
Benjamin BesseJessica J. LinBenjamin J. Solomon
Nature Medicine volume 32（2）, pages682–689
55
Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors
综合基因组测序在晚期实体瘤中的现实临床应用价值
Yuki SaitoSara HorieKeisuke Kataoka
Nature Medicine volume 32（2）, pages690–701
56
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
BCMA CAR-T细胞治疗后，CD4+ T细胞介导CAR-T细胞相关免疫相关不良事件
Matthew HoLuca ParuzzoJoseph A. Fraietta
Nature Medicine volume 32（2）, pages702–716
57
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial
阿贝西利治疗伴有体细胞NF2或CDK通路改变的脑膜瘤：2期联盟A071401试验
Priscilla K. BrastianosKatharine DooleyEvanthia Galanis
Nature Medicine volume 32（2）, pages717–724
58
Clinical genetic variation across Hispanic populations in the Mexican Biobank
墨西哥生物样本库中西班牙裔人群的临床遗传变异
Carmina Barberena-JonasSantiago G. Medina-MuñozAndrés Moreno-Estrada
Nature Medicine volume 32（2）, pages725–735
59
Shared and specific blood biomarkers for multimorbidity
多种共病的共有和特异性血液生物标志物
Alice Margherita OrnagoCaterina GregorioDavide Liborio Vetrano
Nature Medicine volume 32（2）, pages736–745
60
Eliminating opioid prescriptions from outpatient minimally invasive gynecologic surgery: a randomized trial
在门诊微创妇科手术中取消阿片类药物处方：一项随机试验
Andrew ZakhariJade DésiletsFady W. Mansour
Nature Medicine volume 32（2）, pages746–751
61
A multimodal sleep foundation model for disease prediction
用于疾病预测的多模态睡眠基础模型
Rahul ThapaMagnus Ruud KjaerJames Zou
Nature Medicine volume 32（2）, pages752–762
Amendments & Corrections（修订与更正）
62
Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial
作者更正：在已接受治疗的脊髓性肌萎缩症患者中鞘内注射onasemnogene abeparvovec：一项3b期开放标签试验
Jennifer M. KwonFrancina MunellW. Ludo van der Pol
Nature Medicine volume 32（2）, page763
63
Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
作者更正：联合抑制BET家族蛋白和组蛋白去乙酰化酶作为基于表观遗传学的胰腺导管腺癌潜在治疗方法
Pawel K. MazurAlexander HernerJens T. Siveke
Nature Medicine volume 32（2）, pages763–764
64
Publisher Correction: Interpretable inflammation landscape of circulating immune cells
出版商更正：循环免疫细胞可解释的炎症特征
Laura Jiménez-GraciaDavide MasperoHolger Heyn
Nature Medicine volume 32（2）, page765
65
Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer
出版商更正：针对肾癌中缺氧诱导因子2（HIF2）驱动的恶病质的治疗
Muhannad Abu-RemailehLaura A. StranskyWilliam G. Kaelin Jr
Nature Medicine volume 32（2）, page766
66
Publisher Correction: Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
出版商更正：房颤患者抗凝治疗预防缺血性脑卒中及神经认知障碍：BRAIN-AF随机临床试验
Léna RivardPaul KhairyWilliam Liang
Nature Medicine volume 32（2）, page767
67
Editorial Expression of Concern: Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization
编辑关切声明：miR-200s直接靶向Sec23a影响癌细胞分泌组并促进转移性定植
Manav KorpalBrian J. EllYibin Kang
Nature Medicine volume 32（2）, page768
Nature Medicine volume 32 Issue 3
自然医学 32卷 3期
https://www.nature.com/nm/volumes/32/issues/3
Editorial（社论）
1
Keep up the momentum for gene therapies
保持基因疗法的强劲势头
Nature Medicine volume 32(3),page769
News（新闻）
2
Blood tests for Alzheimer’s disease could reshape research and care
阿尔茨海默病的血液检测或可重塑研究与护理模式
Natalie Healey
Nature Medicine volume 32(3), page770-771
News Feature（新闻特写）
3
The AI co-scientist is here
人工智能合作科学家已登场
David Adam
Nature Medicine volume 32(3),pages772–775
Correspondence（读者来信）
4
Unintended risks of sarcopenic obesity during weight-loss interventions in older people
老年人在减肥干预过程中出现肌肉减少性肥胖的意外风险
John A. BatsisLorenzo M. DoniniCarla M. Prado
Nature Medicine volume 32(3),pages776–777
5
PRIMARY-AI: outcomes-based standards to safeguard primary care in the AI era
PRIMARY-AI：基于结果的标准用以保障人工智能时代的基础医疗
Dian ZengLorainne Tudor CarTien Yin Wong
Nature Medicine volume 32(3),pages778–781
6
Professional medical associations as catalytic pathways for advancing women in academic medicine and promoting leadership
专业医学协会：推动女性在医学学术领域发展及提升领导力的催化途径
Fawad A. KhanMargaret T. GopaulMargot Savoy
Nature Medicine volume 32(3),pages782–784
7
An urgent need to build climate and health intervention trial capacity
构建气候与健康干预试验能力的迫切需求
Andy HainesAna BonellZulfiqar Bhutta
Nature Medicine volume 32(3),pages785–786
8
Student-led efforts promoting inclusivity and belonging in US medical schools
美国医学院学生主导促进包容性与归属感的行动
Briana MacedoFelipe Rosero CastroCésar A. Briceño
Nature Medicine volume 32(3),pages787–788
World View（国际视角）
9
Whose ethics govern global health research?
全球卫生研究由谁的伦理规范来主导？
Boghuma Titanji
Nature Medicine volume 32(3), pages789-790
Comment（述评）
10
The new vision from the National Institute of Allergy and Infectious Diseases (NIAID)
美国国家过敏与传染病研究所（NIAID）的新愿景
Jeffery K. TaubenbergerJohn H. PowersJay Bhattacharya
Nature Medicine volume 32(3),pages791–792
11
Asia Pacific perspectives on global health architecture reform
亚太地区对全球卫生架构改革的看法
Indira Dewi KantianaAprajita KaushikAfifah Rahman-Shepherd
Nature Medicine volume 32(3),pages793–796
12
Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy
1型糖尿病成人患者对干细胞衍生胰岛细胞治疗的需求界定
Jane SpeightSufyan HussainMichael Vallis
Nature Medicine volume 32(3),pages797–801
13
Principles to guide clinical AI readiness and move from benchmarks to real-world evaluation
指导临床人工智能准备就绪的原则，以及从基准测试转向真实世界评估的转变
Tej D. AzadHarlan M. KrumholzSuchi Saria
Nature Medicine volume 32(3),pages802–804
News & Views（新闻与观点）
14
Making antibiotic stewardship guidelines work in real-world settings
让抗生素管理指南在现实环境中发挥作用
Ye ZhangPeipei ZhaoDan Wu
Nature Medicine volume 32(3),pages805–806
15
Preventive vaccines for hereditary cancer syndromes
遗传性癌症综合征的预防性疫苗
Yonina R. Murciano-GoroffZsofia K. Stadler
Nature Medicine volume 32(3),pages807–809
16
A daily multivitamin slows the ticking of epigenetic clocks
每日服用复合维生素可减缓表观遗传时钟的“滴答”速度
Daniel W. BelskyCalen P. Ryan
Nature Medicine volume 32(3),pages810–811
17
Base editing milestone for familial hypercholesterolemia
家族性高胆固醇血症的碱基编辑里程碑
Robert S. RosensonSascha N. Goonewardena
Nature Medicine volume 32(3),pages812–813
Research Briefings（研究简报）
18
Somatic loss of the Y chromosome complements polygenic risk scores for type 2 diabetes risk prediction
体细胞Y染色体缺失可补充多基因风险评分用于2型糖尿病风险预测
Nature Medicine volume 32(3),pages814–815
19
Extracorporeal cross-circulation with genetically modified pig livers in a human decedent model
在人类遗体模型中利用基因编辑猪肝脏进行体外交叉循环
Nature Medicine volume 32(3),pages816–817
20
DOPA decarboxylase levels in the cerebrospinal fluid as a diagnostic marker of Lewy body disorders
脑脊液中多巴脱羧酶水平作为路易体病诊断标志物
Nature Medicine volume 32(3),pages818–819
Perspectives（观点）
21
A clinical environment simulator for dynamic AI evaluation
用于动态人工智能评估的临床环境模拟器
Luyang LuoSung Eun KimPranav Rajpurkar
Nature Medicine volume 32(3),pages820–827
Review Articles（综述）
22
Clinical development of cancer vaccines
癌症疫苗的临床开发
John B. HaanenTon N. M. SchumacherCatherine J. Wu
Collection: Cancer at Nature Portfolio
系列专题：自然出版集团癌症专题
Nature Medicine volume 32(3),pages828–840
Articles（论著）
23
Effects of a comprehensive antibiotic stewardship program on antibiotic prescribing for acute respiratory infections in rural facilities: a cluster randomized trial
综合性抗生素管理计划对农村医疗机构急性呼吸道感染抗生素处方的影响：一项整群随机试验
Xiaolin WeiChao ZhuoNanshan Zhong
Nature Medicine volume 32(3),pages841–848
24
Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial
HIV阴性成人结核性脑膜炎的基因型分层辅助地塞米松治疗：一项随机对照3期试验
Joseph DonovanNguyen Duc BangGuy E. Thwaites
Nature Medicine volume 32(3),pages849–858
25
Mass azithromycin distribution and antibiotic resistance in the gut and nasopharynx: a cluster-randomized trial
大规模阿奇霉素分发对肠道和鼻咽部抗生素耐药性的影响：一项整群随机试验
Thuy DoanDaisy YanThomas M. Lietman
Nature Medicine volume 32(3),pages859–868
26
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
Bimagrumab与司美格鲁肽单独或联合治疗肥胖：一项随机2期试验
Steven B. HeymsfieldLouis J. AronneKenneth M. Attie
Nature Medicine volume 32(3),pages869–882
27
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial
一种口服、肝脏限制性LXR反向激动剂治疗血脂异常：临床前开发和1期试验
Xiaoxu LiGiorgia BenegiamoJohan Auwerx
Nature Medicine volume 32(3),pages883–893
28
Genetic regulation across germline and somatic variation on the Y chromosome contributes to type 2 diabetes
Y染色体生殖细胞和体细胞变异的遗传调控对2型糖尿病的影响
Go SatoYuji YamamotoYukinori Okada
Nature Medicine volume 32(3),pages894–905
29
Microfluidic automation improves oocyte recovery from follicular fluid of patients undergoing in vitro fertilization
微流控自动化技术提高体外受精患者卵泡液中卵母细胞的回收率
Baris R. MutluSabrina C. CivaleEmre Ozkumur
Nature Medicine volume 32(3),pages906–914
30
Lay community health worker-led care with mobile decision support for uncontrolled hypertension: a cluster-randomized trial
非专业社区卫生工作者主导、移动决策支持辅助的未控制高血压护理：一项整群随机试验
Felix GerberGiuliana Sanchez-SamaniegoNiklaus Daniel Labhardt
Nature Medicine volume 32(3),pages915–923
31
Remote monitoring of heart failure exacerbations using a smartwatch
使用智能手表远程监测心力衰竭加重情况
Yuan GaoYasbanoo MoayediHeather J. Ross
Nature Medicine volume 32(3),pages924–933
32
An LLM chatbot to facilitate primary-to-specialist care transitions: a randomized controlled trial
一款大型语言模型聊天机器人助力初级到专科诊疗过渡：一项随机对照试验
Xinge TaoShuya ZhouShasha Han
Nature Medicine volume 32(3),pages934–942
33
Holistic evaluation of large language models for medical tasks with MedHELM
使用MedHELM对大型语言模型进行医学任务整体评估
Suhana BediHejie CuiNigam H. Shah
Nature Medicine volume 32(3),pages943–951
34
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial
黑色素瘤新辅助伊匹木单抗联合纳武利尤单抗治疗：2期PRADO试验的5年生存率和生物标志物分析
Lotte L. HoeijmakersPetros DimitriadisChristian U. Blank
Nature Medicine volume 32(3),pages952–963
35
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
多发性骨髓瘤对GPRC5D靶向T细胞衔接器的多模态抗原逃逸
Holly LeeSungwoo AhnNizar J. Bahlis
Nature Medicine volume 32(3),pages964–977
36
Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade
针对肿瘤抗原的体液IgG1反应是免疫检查点阻断临床疗效的基础
Edgar Gonzalez-KozlovaRobert SweeneySacha Gnjatic
Nature Medicine volume 32(3),pages978–991
37
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
Linavonkibart联合帕博利珠单抗治疗免疫检查点阻断耐药性晚期实体瘤：一项1期试验
Timothy A. YapRandy F. SweisLu Gan
Nature Medicine volume 32(3),pages992–1001
38
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial
Nous-209新抗原疫苗预防Lynch综合征携带者癌症：一项1b/2期试验
Anna Morena D’AliseJason WillisEduardo Vilar
Nature Medicine volume 32(3),pages1002–1011
39
Effects of daily multivitamin–multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial
在COSMOS随机临床试验中，每日补充复合维生素-矿物质和可可提取物对表观遗传衰老时钟的影响
Sidong LiRikuta HamayaHoward D. Sesso
Nature Medicine volume 32(3),pages1012–1022
40
A fasting-mimicking diet in patients with mild-to-moderate Crohn’s disease: a randomized controlled trial
模拟禁食饮食对轻中度克罗恩病患者的影响：一项随机对照试验
C. KulkarniT. FardeenS. R. Sinha
Nature Medicine volume 32(3),pages1023–1033
41
Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents
使用转基因异种猪肝脏对脑死亡人类遗体进行体外肝脏交叉循环
Abraham ShakedAlex SagarPeter Friend
Nature Medicine volume 32(3),pages1034–1044
42
In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
杂合子家族性高胆固醇血症体内碱基编辑基因疗法：一项1期试验
Ping WanSiyuan TangQiang Xia
Nature Medicine volume 32(3),pages1045–1051
43
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Obicetrapib治疗杂合子家族性高胆固醇血症：BROOKLYN随机临床试验
Stephen J. NichollsAdam J. NelsonMichael H. Davidson
Nature Medicine volume 32(3),pages1052–1060
44
Single-cell atlas of the developing Down syndrome brain cortex
发育中唐氏综合征大脑皮层的单细胞图谱
Michael LattkeWee Leng TanVincenzo De Paola
Nature Medicine volume 32(3),pages1061–1072
45
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders
用于路易体病诊断的定量多巴脱羧酶生物标志物
Katharina BolsewigGiovanni BellomoCharlotte E. Teunissen
Nature Medicine volume 32(3),pages1073–1084
46
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
利用血浆p-tau217时钟预测症状性阿尔茨海默病的发病
Kellen K. PetersenMarta Milà-AlomàSuzanne E. Schindler
Nature Medicine volume 32(3),pages1085–1094
47
High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial
高剂量诺西那生钠治疗脊髓性肌萎缩症：一项3期随机试验
Richard S. FinkelThomas O. CrawfordStephanie Fradette
Nature Medicine volume 32(3),pages1095–1104
48
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases
抗CD19嵌合抗原受体T细胞治疗儿科难治性自身免疫性疾病
Marco BecilliMarkus MetzlerFranco Locatelli
Nature Medicine volume 32(3),pages1105–1117
49
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
BCMA导向的mRNA嵌合抗原受体T细胞疗法治疗重症肌无力：一项2b期安慰剂对照试验的探索性生物标志物分析
Renee R. FedakRachel N. RuggerieKelly Gwathmey
Nature Medicine volume 32(3),pages1118–1130
50
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial
BCMA导向的mRNA嵌合抗原受体T细胞疗法治疗重症肌无力：一项随机、双盲、安慰剂对照的2b期试验
Tuan VuHacer DurmusJames F. Howard Jr
Nature Medicine volume 32(3),pages1131–1141
51
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial
CD19嵌合抗原受体T细胞治疗难治性自身免疫性疾病：1/2期CASTLE篮式试验
Fabian MüllerMelanie HagenGeorg Schett
Nature Medicine volume 32(3),pages1142–1151
Analysis（分析）
52
LLM-assisted systematic review of large language models in clinical medicine
大型语言模型在临床医学中应用的LLM辅助系统综述
Sully F. ChenAnton AlyakinEric K. Oermann
Nature Medicine volume 32(3),pages1152–1159
Amendments & Corrections（修订与更正）
53
Author Correction: Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study
作者更正：1990 - 2023年全球、区域和国家慢性呼吸系统疾病负担及新冠肺炎疫情的影响：一项全球疾病负担研究
Jiyeon OhSoeun KimDong Keon Yon
Nature Medicine volume 32(3),page1160
54
Author Correction: Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial
作者更正：通过人工智能心电图检测未诊断的肝硬化：一项实用、整群随机临床试验
Douglas A. SimonettoDavid RushlowVijay H. Shah
Nature Medicine volume 32(3),page1160
55
Editorial Expression of Concern: Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers
编辑表达关切：拯救Hippo共激活因子YAP1会触发血液系统癌症中DNA损伤诱导的细胞凋亡
Francesca CottiniTeru HideshimaGiovanni Tonon
Nature Medicine volume 32(3),page1161
Nature Medicine Volume 32 Issue 4
自然医学 32卷 4期
https://www.nature.com/nm/volumes/32/issues/4
Editorial（社论）
1
Show us the evidence for the value of medical AI
展示医疗人工智能价值的证据
Nature Medicine volume 32（4）, page 1163
News（新闻）
2
Mosquito-borne viruses, vaccine-borne hope
蚊媒病毒：疫苗带来希望
Mike May
Nature Medicine volume 32（4）, pages 1164-1165
News Feature（新闻特写）
3
The patient is now in the room
患者已在房间内
Barbara Nasto
Nature Medicine volume 32（4）, pages1166–1169
Correspondence（读者来信）
4
A blueprint to accelerate rare pediatric gene therapy approvals
加速罕见儿科基因疗法审批的蓝图
Mohamed Abou-el-EneinMark C. WaltersDonald B. Kohn
Nature Medicine volume 32（4）, pages1170–1171
5
Physicians as context engineers in the era of generative AI
生成式人工智能时代，医生作为情境工程师
Ivan NenadicMarat FudimJonathan Piccini
Nature Medicine volume 32（4）, pages1172–1173
6
Surviving as a health equity researcher amidst a shifting political climate
在不断变化的政治气候中作为医疗公平研究者的生存
Annesa FlentjeBrian Mustanski
Nature Medicine volume 32（4）, pages1174–1175
7
Precision nutrition must consider cost-effectiveness to deliver benefits to patients
精准营养必须考虑成本效益，才能为患者带来益处
Nicola GuessDan PollardPenny Breeze
Nature Medicine volume 32（4）, pages1176–1177
8
Advancing a new generation of heat-health warning system in China
推进中国新一代高温健康预警系统建设
Tiantian LiRunmei MaHongbing Shen
Nature Medicine volume 32（4）, pages1178–1179
9
Quality health information for all is a fundamental determinant of health
人人享有优质健康信息是健康的根本决定因素
Lawrence O. GostinScott C. RatzanCarolina Batista
Nature Medicine volume 32（4）, pages1180–1181
10
Is AI actually improving healthcare?
人工智能真的在改善医疗保健吗？
Anna GoldenbergJenna Wiens
Nature Medicine volume 32（4）, pages1182–1183
World View（世界观点）
11
Hope, hard lessons and the path to better nutrition
希望、惨痛教训与改善营养之路
Purnima Menon
Nature Medicine volume 32（4）, page1184
Comment（评论）
12
Embedding equity in clinical research governance
将公平性融入临床研究治理
Johanna M. C. BlomCiara StauntonMelodie Labuschaigne
Nature Medicine volume 32（4）, pages1185–1187
13
The role of strategy units in guiding research institutions through complexity
战略部门在引导研究机构应对复杂局面中的作用
Michela Giulia BerteroKatrine Sonne-HansenTeresa Sanchis
Nature Medicine volume 32（4）, pages1188–1190
14
Clinically distinct genetic diseases converge on shared, druggable nodes
临床特征不同的遗传病汇聚于共同的、可药物作用的节点
Jillian L. ShawAnna Greka
Nature Medicine volume 32（4）, pages1191–1193
News & Views（新闻与观点）
15
Engineering in vivo CAR-T cells
体内工程化CAR-T细胞
Beatrice GrecoMatteo DoglioMonica Casucci
Nature Medicine volume 32（4）, pages1194–1195
16
Microbiome modulation in cancer immunotherapy
癌症免疫治疗中的微生物组调节
Sumanta K. PalDiwakar Davar
Nature Medicine volume 32（4）, pages1196–1198
17
Integrating health equity into energy transitions and climate governance
将健康公平性融入能源转型和气候治理
Tiantian LiHang DuPeng Du
Nature Medicine volume 32（4）, pages1199–1200
Research Briefings（研究简报）
18
Modifiable risk factors drive a large share of the global cancer burden
可改变的风险因素是全球癌症负担的主要驱动因素
Nature Medicine volume 32（4）, pages1201–1202
19
The gut microbiome as a fingerprint of antibiotic use history
肠道微生物组是抗生素使用历史的“指纹”
Nature Medicine volume 32（4）, pages1203–1204
20
How inadequate dietary patterns affect global burden of ischemic heart disease
不合理的饮食模式如何影响全球缺血性心脏病的负担
Nature Medicine volume 32（4）, pages1205–1206
21
An atlas to navigate environmental factors and health
一张指引环境因素与健康关系的图谱
Nature Medicine volume 32（4）, pages1207–1208
22
Genes that increase the risk of autism are shared across ancestries
增加自闭症风险的基因在不同族裔中共享
Nature Medicine volume 32（4）, pages1209–1210
Perspectives（观点）
23
Five tenets for advancing evidence-based precision medicine
推进循证精准医学的五大原则
Daniel E. CoralJennifer L. SargentPaul W. Franks
Nature Medicine volume 32（4）, pages1211–1222
24
Target product profiles for treatments to delay or prevent symptomatic Alzheimer’s disease
延缓或预防有症状阿尔茨海默病的治疗的目标产品特征
Jeffrey L. CummingsMichael G. AgadjanyanGeorge Vradenburg
Nature Medicine volume 32（4）, pages1223–1232
Articles（论著）
25
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
非小细胞肺癌日时段免疫化疗：一项随机3期试验
Zhe HuangLiang ZengYongchang Zhang
Nature Medicine volume 32（4）, pages1233–1240
26
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
肌肉浸润性膀胱癌中，伊匹木单抗和纳武利尤单抗联合放化疗用作保膀胱治疗：一项2期试验
Jan-Jaap J. MellemaChantal F. StockemMichiel S. van der Heijden
Nature Medicine volume 32（4）, pages1241–1248
27
A small-molecule inverse agonist of PPARγfor advanced solid tumors: a phase 1 trial
一种用于晚期实体瘤的PPARγ小分子反向激动剂：一项1期试验
Matthew D. GalskyCharlene MantiaXin Gao
Nature Medicine volume 32（4）, pages1249–1256
28
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
复发或难治性多发性骨髓瘤中体内生成抗BCMA CAR-T细胞：一项1期研究
Ning AnDi WangChunrui Li
Nature Medicine volume 32（4）, pages1257–1266
29
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial
Quemliclustat联合化疗有或无zimberelimab治疗转移性胰腺腺癌：一项随机1期试验
Zev A. WainbergGulam A. ManjiEileen M. O’Reilly
Nature Medicine volume 32（4）, pages1267–1277
30
Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial
结肠镜检查和粪便免疫化学检测与常规诊疗在结直肠癌诊断性筛查中的对比：SCREESCO随机对照试验
Marcus WesterbergJonas F. LudvigssonAnna Forsberg
Nature Medicine volume 32（4）, pages1278–1285
31
Real-world clinical utility of tumor whole-genome sequencing in solid cancers
实体癌肿瘤全基因组测序在现实中的临床应用价值
Jeffrey van PuttenPetur SnaebjornssonKim Monkhorst
Nature Medicine volume 32（4）, pages1286–1295
32
AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial
基于人工智能的乳腺癌筛查中乳腺X线摄影和数字断层融合的分级和决策支持：一项配对、非劣效性试验
Esperanza Elías-CabotSara Romero-MartínMarina Álvarez-Benito
Nature Medicine volume 32（4）, pages1296–1305
33
Global and regional cancer burden attributable to modifiable risk factors to inform prevention
可改变的风险因素导致的全球和区域癌症负担，为预防提供依据
Hanna FinkOliver LangseliusIsabelle Soerjomataram
Nature Medicine volume 32（4）, pages1306–1315
34
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial
粪便微生物群移植联合帕博利珠单抗和阿昔替尼治疗转移性肾细胞癌：随机2期TACITO试验
Serena PorcariChiara CiccareseGianluca Ianiro
Nature Medicine volume 32（4）, pages1316–1324
35
Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial
粪便微生物群移植联合免疫疗法治疗转移性肾细胞癌：1期PERFORM试验
Ricardo FernandesBehnam JabbarizadehSaman Maleki Vareki
Nature Medicine volume 32（4）, pages1325–1336
36
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial
粪便微生物群移植联合免疫疗法治疗非小细胞肺癌和黑色素瘤：2期FMT-LUMINate试验
Sreya DuttaguptaMeriem MessaoudeneArielle Elkrief
Nature Medicine volume 32（4）, pages1337–1350
37
Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals
基于14979例个人处方数据的抗生素使用与肠道微生物群组成关联分析
Gabriel BaldanziAnna LarssonTove Fall
Nature Medicine volume 32（4）, pages1351–1361
38
Evaluation of antimicrobial resistance governance across 193 countries to inform the 2026 Global Action Plan update
对193个国家抗菌药物耐药性治理情况评估，为2026年全球行动计划更新提供依据
Weiye ChenYige ZengYongzhang Zhu
Nature Medicine volume 32（4）, pages1362–1373
39
Deciphering the etiology of the 2024 outbreak of undiagnosed febrile illness in Panzi, Democratic Republic of the Congo
解析刚果民主共和国潘济地区2024年不明原因发热疫情的病因
Tony Wawina-BokalangaJean-Claude Makangara-CigoloJean-Jacques Muyembe-Tamfum
Nature Medicine volume 32（4）, pages1374–1382
40
Transmission dynamics of Oropouche virus in Latin America and the Caribbean
奥罗普切病毒在拉丁美洲和加勒比地区的传播动态
Erika R. ManuliXinyi HuaWilliam M. de Souza
Nature Medicine volume 32（4）, pages1383–1392
41
Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine
单剂量四价布坦坦登革热疫苗的长期有效性和安全性
Esper G. KallásJosé A. MoreiraMarcus Vínicius Guimarães de Lacerda
Nature Medicine volume 32（4）, pages1393–1400
42
A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial
基于结构的健康成人尼帕病毒mRNA疫苗：1期试验
Aurélie PloquinRosemarie D. MasonTongqing Zhou
Nature Medicine volume 32（4）, pages 1401–1410
43
Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathy
针对两例严重KCNT1癫痫性脑病患儿的反义寡核苷酸介导的基因敲低疗法
Tojo NakayamaChristelle M. El AchkarTimothy W. Yu
Nature Medicine volume 32（4）, pages1411–1420
44
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
针对LRRK2的反义寡核苷酸治疗帕金森病：1期随机对照试验
Omar S. MabroukBen TichlerDanielle L. Graham
Nature Medicine volume 32（4）, pages1421–1431
45
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial
Zodasiran用于高脂血症患者降低胆固醇和甘油三酯：1期篮式试验最终报告
Gerald F. WattsRussell ScottChristie M. Ballantyne
Nature Medicine volume 32（4）, pages1432–1443
46
Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study
脉冲场消融与传统热消融治疗阵发性心房颤动：ADVENT-LTO研究4年结果
Vivek Y. ReddyEdward P. GerstenfeldMoussa Mansour
Nature Medicine volume 32（4）, pages1444–1453
47
Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990–2023: a Global Burden of Disease study
1990 - 2023年因饮食不理想导致的全球、区域和国家缺血性心脏病负担：一项全球疾病负担研究
Sooji LeeHayeon LeeDong Keon Yon
Nature Medicine volume 32（4）, pages1454–1478
48
Physical activity for public health in the 21st century
21世纪面向公众健康的身体活动
Deborah SalvoInacio Crochemore-SilvaJames Sallis
Nature Medicine volume 32（4）, pages1479–1489
49
Socioeconomic and energy transition disparities in air pollution-related mortality across Europe
欧洲空气污染相关死亡的社会经济和能源转型差异
Zhao-Yue ChenHicham AchebakJoan Ballester
Nature Medicine volume 32（4）, pages1490–1500
50
An atlas of exposome–phenome associations in health and disease risk
健康和疾病风险中暴露组 - 表型组关联图谱
Chirag J. PatelJohn P. A. IoannidisArjun K. Manrai
Nature Medicine volume 32（4）, pages1501–1510
51
Citywide premarital genomic screening in a Middle Eastern population
中东人群的城市范围婚前基因组筛查
Khulood AlblooshiRadwa SharafAhmad Abou Tayoun
Nature Medicine volume 32（4）, pages1511–1518
52
Deleterious coding variation associated with autism is shared across ancestries
与自闭症相关的有害编码变异在不同族裔中共享
Marina Natividad AvilaSeulgi JungJoseph D. Buxbaum
Nature Medicine volume 32（4）, pages1519–1529
53
Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases
双特异性T细胞衔接器治疗难治性自身免疫性结缔组织病
Christina DüsingAndrea-Hermina GyörfiJörg H. W. Distler
Nature Medicine volume 32（4）, pages1530–1542
54
An international mega-analysis of psychedelic drug effects on brain circuit function
迷幻药对大脑回路功能影响的国际大型分析
Manesh GirnManoj K. DossDanilo Bzdok
Nature Medicine volume 32（4）, pages1543–1554
Amendments & Corrections（修正与更正）
55
Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancers
作者更正：实体癌肿瘤全基因组测序在现实中的临床应用价值
Jeffrey van PuttenPetur SnaebjornssonKim Monkhorst
Nature Medicine volume 32（4）, page 1555
56
Author Correction: Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma
作者更正：Wiskott-Aldrich综合征蛋白（WASP）是T细胞淋巴瘤中的肿瘤抑制因子
Matteo MenottiChiara AmbrogioRoberto Chiarle
Nature Medicine volume 32（4）, page 1555
57
Author Correction: Real-time surveillance system for patient deterioration: a pragmatic cluster-randomized controlled trial
作者更正：患者病情恶化实时监测系统：一项实用的整群随机对照试验
Sarah C. RossettiPatricia C. DykesKenrick D. Cato
Nature Medicine volume 32（4）, page 1556
58
Publisher Correction: Clinical development of cancer vaccines
出版商更正：癌症疫苗的临床开发
John B. HaanenTon N. M. SchumacherCatherine J. Wu
Nature Medicine volume 32（4）, page 1557
Nature Medicine Volume 32 Issue 5
自然医学 32卷 5期
https://www.nature.com/nm/volumes/32/issues/5
Editorial（社论）
1
Combating infectious diseases in a fragmented world
在碎片化的世界中抗击传染病
Editorial
Nature Medicine volume 32（5）, page1559
News（新闻）
2
Hope for control of a centuries-old epidemic
控制一场持续数百年的流行病的希望
Barbara Nasto
Nature Medicine volume 32（5）, pages1560-1562
News Feature（新闻专题）
3
Brazil’s big bet on mosquitos
巴西在蚊子身上的重大赌注
Anita Makri
Nature Medicine volume 32（5）, pages1563–1566
Correspondence（读者来信）
4
A reasonably likely surrogate endpoint for metabolic dysfunction–associated steatohepatitis
代谢功能障碍相关脂肪性肝炎的一个可能的合理替代终点
Arun J. SanyalMichelle T. LongTheresa Perney
Nature Medicine volume 32（5）, pages1567–1568
5
The rise and fall of US federally funded human fetal tissue research
美国联邦资助的人类胎儿组织研究的兴衰
Dylan P. ReichertAaron D. Levine
Nature Medicine volume 32（5）, pages1569–1570
6
Making infectious disease data local and as accessible as the weather forecast
让传染病数据像天气预报一样本地化且易于获取
Natalie E. DeanCaitlin M. Rivers
Nature Medicine volume 32（5）, pages1571–1572
7
Local control, remote expertise: governing therapeutic telemedicine in wartime
本地控制，远程专家：战时治疗性远程医疗的治理
Andrea CusumanoOleg ParkhomenkoMarco Lombardo
Nature Medicine volume 32（5）, pages1573–1574
8
Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
巴西消除母婴艾滋病毒传播：对大规模全球卫生体系的启示
Emilia M. JalilValdiléa G. VelosoBeatriz Grinsztejn
Nature Medicine volume 32（5）, pages1575–1576
9
An international and independent scientific foundation for AI governance
一个用于人工智能治理的国际性独立科学基金会
Bilal A. Mateen
Nature Medicine volume 32（5）, pages1577–1578
World View（世界观点）
10
Africa’s moment for health security
非洲卫生安全的关键时刻
Jean Kaseya
Nature Medicine volume 32（5）, pages1579
Comment（评论）
11
A genomics health strategy for the Arabian Gulf
阿拉伯海湾地区的基因组学健康战略
Hamad AliBarrak AlahmadAhmad Abou Tayoun
Nature Medicine volume 32（5）, pages1580–1582
12
HPV vaccines, 20 years on
HPV疫苗，二十年回顾
Karen Canfell
Nature Medicine volume 32（5）, pages1583–1585
13
Closing the gap on antifungal resistance
缩小抗真菌耐药性的差距
Paul E. VerweijAna Alastruey-IzquierdoDarius Armstrong‑James
Nature Medicine volume 32（5）, pages1586–1591
News & Views（新闻与观点）
14
Uncovering risk factors in the exposome for early-onset colorectal cancer
揭示早发性结直肠癌暴露组中的风险因素
David J. LeeSylvan BacaKimmie Ng
Nature Medicine volume 32（5）, pages1592–1593
15
Modifying exposure to plastic-associated chemicals in daily living
在日常生活中减少塑料相关化学品的暴露
Eliane El HayekMatthew CampenBethany Jorgensen
Nature Medicine volume 32（5）, pages1594–1595
16
Rethinking triage for febrile children in low-resource settings
重新思考资源匮乏地区发热儿童的分诊策略
Mihir R. AtreyaLuregn J. Schlapbach
Nature Medicine volume 32（5）, pages1596–1597
17
The ghost of tuberculosis past
结核病的昔日幽灵
Anete TrajmanJonathon R. Campbell
Nature Medicine volume 32（5）, pages1598–1599
Research Briefings（研究简报）
18
ChatGPT Health triage advice falls short in key cases
ChatGPT健康分诊建议在关键病例中表现不佳
Nature Medicine volume 32（5）, pages1600–1601
19
A biomarker of Alzheimer’s disease could be a useful diagnostic tool for other amyloidoses
阿尔茨海默病的生物标志物可作为其他淀粉样变性的有用诊断工具
Nature Medicine volume 32（5）, pages1602–1603
20
Early kidney risk prediction in APOL1 high-risk genotype carriers
APOL1高风险基因型携带者的早期肾脏风险预测
Nature Medicine volume 32（5）, pages1604–1605
21
Intestinal metaplasia is the only precursor to esophageal adenocarcinoma
肠化生是食管腺癌的唯一癌前病变
Nature Medicine volume 32（5）, pages1606–1607
22
Exposure to negative physical and social factors accelerates brain aging
暴露于身体和社会负面因素会加速大脑衰老
Nature Medicine volume 32（5）, pages1608–1609
Perspectives（观点）
23
Global vaccine development
全球疫苗开发
Jerome H. KimNicaise Ndembi
Nature Medicine volume 32（5）, pages1610–1622
24
The future of diagnostics in Africa
非洲诊断学的未来
Yenew KebedeNqobile NdlovuTrevor Peter
Nature Medicine volume 32（5）, pages1623–1633
Review Articles（综述）
25
Climate change and infectious diseases
气候变化与传染病
Rachel E. BakerAleksandra R. StamperC. Jessica E. Metcalf
Nature Medicine volume 32（5）, pages1634–1645
26
Global approaches to infectious disease surveillance and modeling
传染病监测和建模的全球方法
Mark P. KhuranaJoseph L.-H. TsuiMoritz U. G. Kraemer
Nature Medicine volume 32（5）, pages1646–1660
Brief Communications（短评）
27
Rapid expansion of genotype D1.1A(H5N1) influenza viruses in wild birds across North America during the 2024 migratory season
2024年迁徙季节期间D1.1 A(H5N1)基因型流感病毒在北美野鸟中的快速扩张
Walter N. HarringtonAnthony SignoreRichard J. Webby
Nature Medicine volume 32（5）, pages1661–1665
28
Evidence of monkeypox virus clade IIb lineage A.2.2 in the Republic of the Congo and co-circulation of clade Ia, Ib and clade IIb
刚果共和国发现猴痘病毒IIb分支A.2.2系以及Ia、Ib和IIb分支的共同传播的证据
Felix Koukouikila-KoussoundaClaude Kwe YindaFabien Roch Niama
Nature Medicine volume 32（5）, pages1666–1670
29
ChatGPT Health performance in a structured test of triage recommendations
ChatGPT健康在结构化分诊建议测试中的表现
Ashwin RamaswamyAlvira TyagiGirish N. Nadkarni
Nature Medicine volume 32（5）, pages1671–1675
30
Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis
血液磷酸化tau升高作为免疫球蛋白轻链和转甲状腺素蛋白淀粉样变性的生物标志物
Stephan A. KaeserStephanie A. SchultzMathias Jucker
Nature Medicine volume 32（5）, pages1676–1681
31
Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes
胰高血糖素样肽-1受体激动剂对1型糖尿病患者主要心血管和肾脏预后的影响
Yunwen XuNatalie Daya MalekJung-Im Shin
Nature Medicine volume 32（5）, pages1682–1685
Articles（论著）
32
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial
塞马格鲁肽对肝纤维化高风险患者肝脏纤维化和心脏预后的影响：SELECT随机试验的预设分析
Sebastian M. MeyhöferBertrand CariouChristoffer W. Tornøe
Nature Medicine volume 32（5）, pages1686–1693
33
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial
NPR1激动剂抗体XXB750治疗心力衰竭：一项2期随机试验
Scott D. SolomonJohn J. V. McMurrayMartin P. Lefkowitz
Nature Medicine volume 32（5）, pages1694–1700
34
Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes
蛋白质组学风险评分用于APOL1高风险基因型个体肾病进展的早期预测
Chenyu LiShola M. RichardsKatalin Susztak
Nature Medicine volume 32（5）, pages1701–1707
35
The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial
TREM2激动性抗体AL002治疗早期阿尔茨海默病：一项2期随机试验
Catherine J. MummeryArthur J. MayorgaGiacomo Salvadore
Nature Medicine volume 32（5）, pages1708–1716
36
A cognitive layer architecture to support large-language model performance in psychotherapy interactions
支持大语言模型在心理治疗交互中表现的认知层架构
Max RollwageJessica McFadyenRoss Harper
Nature Medicine volume 32（5）, pages1717–1725
37
Advancing conversational diagnostic AI with multimodal reasoning
利用多模态推理推进会话式诊断人工智能
Khaled SaabChunjong ParkRyutaro Tanno
Nature Medicine volume 32（5）, pages1726–1736
38
AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial
基于人工智能的胸部X线在肺癌诊断路径中的优先级排序：LungIMPACT随机对照试验
Nick WoznitzaLesley SmithDavid R. Baldwin
Nature Medicine volume 32（5）, pages1737–1744
39
Enhanced dynamic risk stratification of smoldering multiple myeloma
冒烟型多发性骨髓瘤的增强动态风险分层
Floris ChabrunDaniel E. SchwartzIrene M. Ghobrial
Nature Medicine volume 32（5）, pages1745–1753
40
Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas
液体活检用于地方性区域EBV阳性伯基特淋巴瘤的诊断
Clara ChambaHeavenlight ChristopherAnna Schuh
Nature Medicine volume 32（5）, pages1754–1762
41
CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
CRISPR-Cas9 CD33敲除异基因造血干细胞移植联合吉妥珠单抗 Ozogamicin 维持治疗AML：一项1/2期试验
John F. DiPersioGuenther KoehneBrenda W. Cooper
Nature Medicine volume 32（5）, pages1763–1772
42
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial
伊沙妥昔单抗、卡非佐米、来那度胺和地塞米松治疗新诊断多发性骨髓瘤：一项随机3期试验
Francesca GayWilfried RoeloffzenAnnemiek Broijl
Nature Medicine volume 32（5）, pages1773–1782
43
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial
帕博利珠单抗和奥拉帕利治疗同源重组缺陷转移性胰腺癌：2期POLAR试验
Wungki ParkCatherine A. O’ConnorEileen M. O’Reilly
Nature Medicine volume 32（5）, pages1783–1793
44
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Elraglusib联合化疗治疗转移性胰腺导管腺癌：一项随机对照2期试验
Devalingam MahalingamRachna T. ShroffTanios S. Bekaii-Saab
Nature Medicine volume 32（5）, pages1794–1804
45
Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma
整合流行病学和分子数据揭示食管腺癌癌前状态与癌症状态之间的关系
Shahriar A. ZamaniLianlian WuRebecca C. Fitzgerald
Nature Medicine volume 32（5）, pages1805–1816
46
Implementation of the NHS England Lung Cancer Screening Programme over 5 years
NHS英格兰肺癌筛查计划五年实施情况
Richard W. LeeArjun NairTim Windle
Nature Medicine volume 32（5）, pages1817–1826
47
Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure
表观遗传指纹将早发性结直肠癌与农药暴露联系起来
Silvana C. E. MaasIosune BaraibarJose A. Seoane
Nature Medicine volume 32（5）, pages1827–1837
48
The exposome of brain aging across 34 countries
横跨34个国家的大脑衰老暴露组
Agustina LegazSebastian MoguilnerAgustin Ibanez
Nature Medicine volume 32（5）, pages1838–1851
49
A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia
一种深度联合学习蛋白质组学模型用于诊断六种与痴呆相关的疾病
Lijun AnAlexa Pichet BinetteJacob W. Vogel
Nature Medicine volume 32（5）, pages1852–1864
50
Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial
玻璃体内光开关疗法治疗晚期视网膜色素变性：一项1期开放标签试验
Robert J. CassonEric DanielsRussell N. Van Gelder
Nature Medicine volume 32（5）, pages1865–1870
51
Low-plastic diet and urinary levels of plastic-associated phthalates and bisphenols: the randomized controlled PERTH Trial
低塑料饮食与尿液中塑料相关邻苯二甲酸酯和双酚水平：随机对照PERTH试验
Amelia J. HarrayAndrew D. LucasMichaela Lucas
Nature Medicine volume 32（5）, pages1871–1883
52
Diet–microbiome associations in 10,068 individuals from the Human Phenotype Project to guide personalized nutrition
来自人类表型项目的10,068例个体的饮食-微生物组关联分析，以指导个性化营养
Tomer SegevDaniel BarakEran Segal
Nature Medicine volume 32（5）, pages1884–1894
53
Cross-reactive anti-prophage antibodies and bacterial heteroresistance implicated in phage therapeutic failure
交叉反应性抗前噬菌体抗体和细菌异质性耐药与噬菌体治疗失败有关
F. Gordillo AltamiranoD. SubediA. Y. Peleg
Nature Medicine volume 32（5）, pages1895–1906
54
Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia
预测南亚和东南亚资源匮乏社区环境中发热儿童的转诊需求
Arjun ChandnaConstantinos KoshiarisSakib Burza
Nature Medicine volume 32（5）, pages1907–1916
55
Genomic epidemiology of the 2025 mpox epidemic in Sierra Leone
2025年塞拉利昂猴痘流行的基因组流行病学
Allan K. O. CampbellJohn Demby SandiDonald S. Grant
Nature Medicine volume 32（5）, pages1917–1926
56
Long-term risk of death after tuberculosis diagnosis and treatment
结核病诊断和治疗后的长期死亡风险
Thiago Cerqueira-SilvaViviane Sampaio BoaventuraJulia M. Pescarini
Nature Medicine volume 32（5）, pages1927–1934
Amendments & Corrections（修订与更正）
57
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
作者更正：Obicetrapib治疗杂合子家族性高胆固醇血症患者：BROOKLYN随机临床试验
Stephen J. NichollsAdam J. NelsonMichael H. Davidson
Nature Medicine volume 32（5）, page1935
58
Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial
作者更正：高剂量努西奈森治疗脊髓性肌萎缩症：一项3期随机试验
Richard S. FinkelThomas O. CrawfordStephanie Fradette
Nature Medicine volume 32（5）, page1936
59
Publisher Correction: Reliability of LLMs as medical assistants for the general public: a randomized preregistered study
出版商更正：大语言模型作为公众医疗助手的可靠性：一项随机预注册研究
Andrew M. BeanRebecca Elizabeth PayneAdam Mahdi
Nature Medicine volume 32（5）, page1937
60
Editorial Expression of Concern: Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions
社论关注表达：孤立小肠段支持辅助肝脏并维持肝功能
Brigid JosephEkaterine BerishviliSanjeev Gupta
Nature Medicine volume 32（5）, page1938
Nature Medicine Volume 32 Issue 6
自然医学 32卷 6期
https://www.nature.com/nm/volumes/32/issues/6
Editorial（社论）
1
Medical innovation in LMICs: can India lead the way?
中低收入国家的医疗创新：印度能否引领发展？
Nature Medicine volume 32（6）, page1939
News（新闻）
2
At last, a pipeline for treating kidney disease
肾病治疗药物管线终于建成
Carrie Arnold
Nature Medicine volume 32（6）, pages1940-1941
News Feature（新闻专题）
3
Who owns my health data?
我的健康数据归谁所有？
Paul Webster
Nature Medicine volume 32（6）, pages 1942–1945
Correspondence（读者来信）
4
The Q-MONSTAR consortium: advancing fault-tolerant quantum computing for precision oncology
Q-MONSTAR联盟：研发容错量子计算技术助力精准肿瘤学
Mitsuho ImaiRiu YamashitaTakayuki Yoshino
Nature Medicine volume 32（6）, pages1946–1947
5
How to meaningfully evaluate AI in clinical medicine
如何对临床医学人工智能开展有实际意义的评估
Mahmud OmarReem AgbareiaGirish N. Nadkarni
Nature Medicine volume 32（6）, pages1948–1949
6
Ten lessons from a decade of scientific translation at the Crick
克里克研究所十年科研转化的十条经验
Stephen MayhewDave AllenDavid Roblin
Nature Medicine volume 32（6）, pages1950–1951
7
The value of patient-focused drug development
以患者为中心开展药物研发的价值
Allison MartinRuss Paulsen
Nature Medicine volume 32（6）, pages1952–1953
8
The TARGET guideline for reporting observational studies of interventions
干预性观察研究报告规范TARGET指南
Harrison J. HansfordJames H. McAuleyAidan G. Cashin
Nature Medicine volume 32（6）, pages1954–1955
9
Naming in medicine: how disease nomenclature shapes diagnosis, research and patient lives
医学命名：疾病命名体系如何影响临床诊断、科研进展与患者生活
Helena TeedeRachel MormanElisabet Stener-Victorin
Nature Medicine volume 32（6）, pages1956–1957
World View（全球视野）
10
When cure exists but access does not
有药可医，却无药可用
Ali T. Taher
Nature Medicine volume 32（6）, page1958
Comment（评论）
11
Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care
肥胖管理数据决策支持委员会：推动更加公平、个体化的肥胖诊疗
Paul W. FranksSara G. I. SulimanCarel W. le Roux
Nature Medicine volume 32（6）, pages1959–1961
12
Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update
欧洲肥胖研究学会（EASO）肥胖及其并发症药物治疗框架：2026版更新
Andreea CiudinJennifer L. BakerBarbara McGowan
Nature Medicine volume 32（6）, pages1962–1966
13
The arrival of digital twins and in silico trials in drug development
数字孪生与虚拟临床试验走进药物研发领域
Ashley L. EadieHolly Fernandez LynchRavi B. Parikh
Nature Medicine volume 32（6）, pages1967–1971
14
Clinical trials for continuously monitored and updated AI systems
面向持续监测与迭代更新人工智能系统的临床试验设计
Wouter A. C. van AmsterdamMichael OberstAnna Goldenberg
Nature Medicine volume 32（6）, pages1972–1974
News & Views（新闻与观点）
15
Translating ‘food is medicine’ from concept to reality
把“食物即是良药”从理念落地为现实
Juliet CushingWendelin SlusserTannaz Moin
Nature Medicine volume 32（6）, pages1975–1976
16
A new treatment for preterm pre-eclampsia could benefit mother and child
早产子痫前期新疗法有望惠及母婴双方
Meryam SugulleAnne Cathrine Staff
Nature Medicine volume 32（6）, pages1977–1978
17
Harnessing the power of biomarkers for diffuse intrinsic pontine gliomas
挖掘生物标志物价值，用于弥漫性内生型桥脑胶质瘤研究
Jasia Mahdi
Collection: Cancer at Nature Portfolio
专题合集：自然旗下期刊肿瘤研究专辑
Nature Medicine volume 32（6）, pages1979–1980
18
Integrating public health into house design
将公共卫生理念融入住宅设计
Nelli WestercampJohn E. Gimnig
Nature Medicine volume 32（6）, pages1981–1982
Research Briefings（研究简报）
19
Microglia at a key inflection point in Alzheimer’s disease
小胶质细胞迎来阿尔茨海默病研究的关键转折点
Nature Medicine volume 32（6）, pages1983–1984
20
Blood signatures of cell type-specific aging forecast disease risk and resilience
细胞特异性衰老血液特征可预测患病风险与机体抗逆能力
Nature Medicine volume 32（6）, pages1985–1986
21
Gut microbiome screens could identify risk of Parkinson’s disease years before symptoms appear
肠道微生物筛查可在帕金森病出现症状多年前识别患病风险
Nature Medicine volume 32（6）, pages1987–1988
22
A data-driven risk stratification framework for clinical obesity
面向肥胖临床诊疗的数据驱动型风险分层体系
Nature Medicine volume 32（6）, pages1989–1990
23
Pathogenic germline variants identify elevated cancer risk in pediatric patients referred for genetic testing
致病性生殖系变异可提升接受基因检测儿童患者的肿瘤患病风险检出率
Nature Medicine volume 32（6）, pages1991–1992
24
Autonomous pathology research using agentic AI shows potential in oncology
智能自主AI助力病理学研究，在肿瘤领域展现应用前景
Nature Medicine volume 32（6）, pages1993–1994
25
The Hong Kong Genome Project is a flagship initiative for precision medicine in Chinese populations
香港基因组计划：华人人群精准医学的旗舰项目
Nature Medicine volume 32（6）, pages1995–1996
Perspectives（观点）
26
AI-induced never-skilling in medical education
AI引发医学教育中的“技能零习得”困境
Yuhe KeLiyuan JinNan Liu
Nature Medicine volume 32（6）, pages1997–2006
Review Articles（综述）
27
Resetting autoimmune disease with CAR cell therapies
利用CAR细胞疗法重塑自身免疫病治疗格局
Georg SchettHuji Xu
Nature Medicine volume 32（6）, pages2007–2016
Articles（论著）
28
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
贝那利珠单抗对比安慰剂治疗嗜酸性粒细胞增多综合征：一项随机、安慰剂对照III期临床试验
Princess U. OgboguFlorence RoufosseAmy D. Klion
Nature Medicine volume 32（6）, pages2017–2025
29
Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial
低剂量口服烟酰胺单核苷酸治疗免疫性血小板减少症：I/II期临床试验
Huiyuan LiYuan XuLei Zhang
Nature Medicine volume 32（6）, pages2026–2036
30
Performance of traumatic encephalopathy syndrome criteria in identifying individuals with chronic traumatic encephalopathy
创伤性脑病综合征诊断标准对慢性创伤性脑病患者的识别效能
John D. ArenaWilliam StewartDouglas H. Smith
Nature Medicine volume 32（6）, pages2037–2046
31
Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience
β淀粉样蛋白-tau病理拐点处人类小胶质细胞的转化特征，对应痴呆发病与疾病抵抗的不同通路
Ashley LuWei-Ting ChenBart De Strooper
Nature Medicine volume 32（6）, pages2047–2059
32
Plasma proteomic signatures of cellular aging predict human disease
Daisy Yi DingVeronica Augustina BotTony Wyss-Coray
细胞衰老的血浆蛋白质组学特征可预测人类疾病发生风险
Series: Global Neurodegeneration Proteomics Consortium
系列专题：全球神经退行性疾病蛋白质组学联盟
Nature Medicine volume 32（6）, pages2060–2072
33
A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism
多模态生物标志物方案提升神经退行性帕金森病的诊断精准度
Ivan Martinez-ValbuenaMaziar EmamikhahAnthony E. Lang
Nature Medicine volume 32（6）, pages2073–2082
34
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration
脑脊液乙酰化Tau-174生物标志物可区分额颞叶变性患者的TDP-43蛋白与tau蛋白病理类型
Madison I. J. HoneyYanaika S. Hok-A-HinCharlotte E. Teunissen
Nature Medicine volume 32（6）, pages2083–2095
35
Microbiome signature of Parkinson’s disease in healthy and genetically at-risk individuals
健康人群及高遗传风险人群中帕金森病的微生物组特征
Elisa MenozziYani RenAnthony H. V. Schapira
Nature Medicine volume 32（6）, pages2096–2106
36
Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial
灭活嗜黏蛋白阿克曼菌MucT用于超重与肥胖人群的体重维持：一项随机对照试验
Sarah MountEmanuel E. CanforaEllen E. Blaak
Nature Medicine volume 32（6）, pages2107–2116
37
Data-driven prioritization of high-risk individuals for weight loss interventions
依托大数据筛选优先开展减重干预的高危人群
Kamil DemircanJulia Carrasco-ZaniniClaudia Langenberg
Nature Medicine volume 32（6）, pages2117–2127
38
DASH-patterned groceries and effects on blood pressure in adults treated for hypertension: the GoFreshRx randomized trial
得舒饮食模式生鲜食材对高血压患者血压的影响：GoFreshRx随机临床试验
Stephen P. JuraschekHannah ColStephanie L. Fitzpatrick
Nature Medicine volume 32（6）, pages2128–2136
39
AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial
AAV基因疗法治疗纯合子家族性高胆固醇血症：I期临床试验
Tao ZhengGe GaoYue Wu
Nature Medicine volume 32（6）, pages2137–2146
40
Medically tailored meals receipt and healthcare utilization and costs in Massachusetts’ Medicaid demonstration
马萨诸塞州医疗补助试点项目：定制医学膳食与医疗资源利用及医疗成本分析
Kurt HagerMatthew AlcuskyDariush Mozaffarian
Nature Medicine volume 32（6）, pages2147–2154
41
Time-restricted eating for body weight management in women with polycystic ovary syndrome: a randomized controlled trial
限时进食对多囊卵巢综合征女性体重的调控效果：随机对照试验
Sarah CorapiMary-Claire RuncheySofia Cienfuegos
Nature Medicine volume 32（6）, pages2155–2163
42
Assessing quality of childbirth care provided by skilled health personnel in Exemplar countries
模范国家内持证医务工作者分娩照护服务质量评估
Laith Hussain-AlkhateebYao HeDavid E. Phillips
Nature Medicine volume 32（6）, pages2164–2172
43
Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial
靶向清除可溶性血管内皮生长因子受体1治疗极早发型子痫前期：一项预试验
Ravi ThadhaniThomas F. HiemstraS. Ananth Karumanchi
Nature Medicine volume 32（6）, pages2173–2181
44
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
zolbetuximab联合mFOLFOX6方案+纳武利尤单抗一线治疗CLDN18.2阳性不可切除胃及胃食管结合部腺癌：II期临床试验
Kohei ShitaraHirokazu ShojiSamuel J. Klempner
Nature Medicine volume 32（6）, pages2182–2190
45
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial
成纤维细胞生长因子受体抑制剂治疗琥珀酸脱氢酶缺陷型胃肠间质瘤：II期临床试验
Priscilla MerriamJames J. MorrowSuzanne George
Nature Medicine volume 32（6）, pages2191–2200
46
Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial
靶向治疗联合放疗治疗弥漫性内生型桥脑胶质瘤：随机II期BIOMEDE临床试验
Marie-Anne DebilyGwenael Le TeuffJacques Grill
Nature Medicine volume 32（6）, pages2201–2215
47
Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial
靶向肿瘤的干扰素α基因疗法治疗胶质母细胞瘤：I期临床试验
Bernhard GentnerMarica EoliLuigi Naldini
Nature Medicine volume 32（6）, pages2216–2226
48
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial
曲贝替定联合低剂量伊立替康靶向抑制EWS::FLI1融合基因治疗尤因肉瘤：I/II期临床试验
Patrick J. GroharRachel HeiseRashmi Chugh
Nature Medicine volume 32（6）, pages2227–2237
49
Pathogenic germline variations and cancer risks in pediatric patients referred for genetic testing
接受基因检测的儿科患者致病性生殖系变异与肿瘤发病风险研究
Huijun WangXinran DongWenhao Zhou
Nature Medicine volume 32（6）, pages2238–2244
50
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial
戈替司他对比多西他赛治疗转移性鳞状非小细胞肺癌：随机III期PRESERVE-003试验第一阶段研究
Byoung Chul ChoRama BalaramanYi-Long Wu
Nature Medicine volume 32（6）, pages2245–2253
51
An agentic framework for autonomous scientific discovery in cancer pathology
面向肿瘤病理学自主科研发现的智能运行框架
Florian TrostBide ZhangYuri Tolkach
Nature Medicine volume 32（6）, pages2254–2266
52
A socially assistive robot to support mental wellbeing in LGBTQ+ young people at risk of self-harm: a randomized controlled trial
社交辅助机器人改善存在自伤风险性少数青少年心理健康：随机对照试验
A. Jess WilliamsC. Aubrey RhodesPetr Slovak
Nature Medicine volume 32（6）, pages2267–2276
53
Population-scale genomic medicine with the Hong Kong Genome Project
依托香港基因组计划开展人群规模基因组医学研究
Dingge YingChing-Lung CheungBrian Hon Yin Chung
Nature Medicine volume 32（6）, pages2277–2287
54
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants
SGLT2抑制剂对心肌病遗传变异携带者新发心力衰竭的影响
Nicholas A. MarstonShinwan KanyChristian T. Ruff
Nature Medicine volume 32（6）, pages2288–2293
55
A sustainable house design to improve child health in rural Africa: a cluster-randomized controlled trial
非洲农村地区改善儿童健康的可持续住宅设计：整群随机对照试验
Salum MshamuMavuto MukakaLorenz von Seidlein
Nature Medicine volume 32（6）, pages2294–2301
Resources（资源数据库）
56
The All of Us Research Program’s wearables dataset
全民健康研究项目可穿戴设备数据集
Theresa PattenEdward A. PrebleAmy Rose Price
Nature Medicine volume 32（6）, pages2302–2310
57
Plasma proteomic signature of the human menstrual cycle
人类月经周期的血浆蛋白质组特征
Iben RiishedeLine RodeJonas Ghouse
Nature Medicine volume 32（6）, pages 2311–2318
Amendments & Corrections（修订与勘误）
58
Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
作者勘误：贝那利珠单抗对比安慰剂治疗嗜酸性粒细胞增多综合征：一项随机、安慰剂对照III期临床试验
Princess U. OgboguFlorence RoufosseAmy D. Klion
Nature Medicine volume 32（6）, page 2319
100 项与 Elraglusib 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期恶性实体瘤 | 临床2期 | - | 2026-10-01 | |
| 转移性胰腺导管腺癌 | 临床2期 | 美国 | 2025-05-30 | |
| 转移性黑色素瘤 | 临床2期 | 美国 | 2023-05-31 | |
| 转移性黑色素瘤 | 临床2期 | 美国 | 2023-05-31 | |
| 转移性胰腺腺癌 | 临床2期 | 美国 | 2022-03-21 | |
| 转移性骨肉瘤 | 临床2期 | 美国 | 2022-03-01 | |
| 小细胞肉瘤 | 临床2期 | 美国 | 2022-03-01 | |
| 晚期胰腺腺癌 | 临床2期 | 美国 | 2022-01-26 | |
| 晚期胰腺腺癌 | 临床2期 | 美国 | 2022-01-26 | |
| 胰腺导管腺癌 | 临床2期 | 美国 | 2022-01-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 233 | Elraglusib plus Gemcitabine/Nab-paclitaxel | 遞餘築廠醖獵廠糧鏇積(壓鑰願蓋餘窪壓膚積淵) = 憲鑰鏇鑰製淵憲窪積憲 繭顧鏇築蓋鬱艱艱醖鏇 (憲夢夢鬱觸蓋窪醖鏇獵 ) 更多 | 积极 | 2026-05-29 | ||
Gemcitabine/Nab-paclitaxel | 遞餘築廠醖獵廠糧鏇積(壓鑰願蓋餘窪壓膚積淵) = 繭蓋餘衊選築鏇遞獵襯 繭顧鏇築蓋鬱艱艱醖鏇 (憲夢夢鬱觸蓋窪醖鏇獵 ) 更多 | ||||||
临床2期 | 49 | FFX alone | 獵餘蓋蓋廠憲壓鏇淵憲(觸蓋襯鑰夢夢選鹹糧窪) = 遞膚襯齋選齋簾網餘憲 廠齋鹽製淵夢遞積鬱顧 (壓餘蓋鹽鏇淵構膚蓋艱, 1.1 ~ NR) 更多 | 积极 | 2026-05-29 | ||
FFX plus LOS (50 mg daily) | 獵餘蓋蓋廠憲壓鏇淵憲(觸蓋襯鑰夢夢選鹹糧窪) = 簾築廠壓遞齋餘遞網願 廠齋鹽製淵夢遞積鬱顧 (壓餘蓋鹽鏇淵構膚蓋艱, 1.6 ~ 9.9) 更多 | ||||||
临床2期 | 233 | 衊選製醖遞鑰製廠鹽築(壓憲窪獵襯範齋鑰醖鹽) = 選鬱齋構衊選鹹積構鑰 蓋糧觸獵網衊積鬱獵遞 (鏇簾夢構鏇餘壓窪壓憲 ) 更多 | 积极 | 2026-04-14 | |||
衊選製醖遞鑰製廠鹽築(壓憲窪獵襯範齋鑰醖鹽) = 廠獵築構積憲壓選構糧 蓋糧觸獵網衊積鬱獵遞 (鏇簾夢構鏇餘壓窪壓憲 ) 更多 | |||||||
临床2期 | 170 | 選鹹廠鬱獵製鏇遞壓簾(積齋鏇鹹範鑰壓廠齋蓋) = KRAS and TP53 gene mutations were associated with worse overall survival (OS) in patients treated with elraglusib/GnP (p<0.05) but not in GnP-treated patients. 壓憲蓋繭鬱簾繭蓋齋廠 (網顧蓋積齋餘壓餘醖夢 ) | 积极 | 2026-01-08 | |||
Gemcitabine/nab-paclitaxel | |||||||
临床1期 | 10 | 鏇範繭壓鬱選觸衊選淵(築製觸壓憲膚衊築鹹鏇) = 顧蓋襯醖窪艱鹹餘鏇淵 齋鑰蓋範窪鹽製鹹願鏇 (衊憲願鑰窪夢製糧鏇獵 ) 更多 | 积极 | 2025-07-17 | |||
临床2期 | 7 | 觸鹽築積積膚夢衊製獵 = 願糧願夢廠糧鬱範壓窪 選網襯鹹醖蓋膚築襯窪 (窪願衊製糧構鬱衊窪衊, 鏇膚衊壓繭夢簾膚餘壓 ~ 遞夢構製鹹網糧蓋簾鏇) 更多 | - | 2025-07-17 | |||
临床2期 | 转移性胰腺导管腺癌 CA 19-9 levels | IFNβ | PD-L1 | - | Elraglusib 9.3 mg/kg IV once weekly + Gemcitabine/nab-paclitaxel | 製醖淵顧糧廠積衊襯餘(鏇醖鑰衊憲鏇衊衊鏇餘) = 鹽鹽鬱構膚膚鏇繭廠製 鏇窪蓋鹹鏇鏇蓋蓋窪觸 (膚遞廠齋糧廠鏇膚鏇齋 ) 更多 | 积极 | 2025-05-30 | |
Gemcitabine/nab-paclitaxel | 製醖淵顧糧廠積衊襯餘(鏇醖鑰衊憲鏇衊衊鏇餘) = 遞壓壓網築餘積憲壓範 鏇窪蓋鹹鏇鏇蓋蓋窪觸 (膚遞廠齋糧廠鏇膚鏇齋 ) 更多 | ||||||
临床2期 | 转移性胰腺癌 一线 | - | 網襯積簾餘夢鬱醖衊艱(選願窪襯鬱憲齋廠遞顧) = elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) met the primary endpoints and achieved statistical significance in topline results. 獵壓鹽憲製齋獵淵糧顧 (窪願廠餘淵築遞鹹憲鏇 ) 达到 | 积极 | 2025-05-09 | ||
临床2期 | 唾液腺肿瘤 tumor PD-L1 | GSK-3β expression | 32 | 鏇夢鬱襯艱築憲獵鑰憲(顧廠衊構壓築襯窪鑰淵) = 廠膚鹽觸觸襯築鹹醖鏇 糧積簾範構襯淵範製淵 (構範遞網糧願壓遞膚廠, 2 ~ 25) 更多 | 积极 | 2025-04-29 | ||
临床2期 | 胰腺癌 一线 | 286 | Elraglusib + gemcitabine/nab-paclitaxel | 鏇繭製範淵夢築憲糧鹹(網醖築鹹簾膚選蓋憲窪) = 願壓範窪獵艱觸壓簾網 遞餘蓋夢淵範鹹齋窪觸 (夢網憲糧繭膚齋構衊夢 ) 达到 更多 | 积极 | 2024-12-17 | |
gemcitabine/nab-paclitaxel | 鏇繭製範淵夢築憲糧鹹(網醖築鹹簾膚選蓋憲窪) = 繭簾膚淵獵製遞積鏇積 遞餘蓋夢淵範鹹齋窪觸 (夢網憲糧繭膚齋構衊夢 ) 达到 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用